ELEVATED BLOOD EOSINOPHILS AND SERUM IGE LEVELS AS BIOMARKERS IN PREDICTION OF COPD EXACERBATIONS

Dissertation submitted In Partial Fulfilment of the

Requirements for the Degree of

DOCTOR OF MEDICINE

TUBERCULOSIS & RESPIRATORY MEDICINE

Branch – XVII

2015-2018

DEPARTMENT OF TUBERCULOSIS & RESPIRATORY MEDICINE

Government Stanley Medical College & Hospital

Chennai - 600001

THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY CHENNAI-600032

April 2018

CERTIFICATE

This is to certify that the dissertation on

"ELEVATED BLOOD EOSINOPHILS & SERUM IgE LEVELS AS BIOMARKERS IN PREDICTION OF COPD EXACERBATION "

is a record of research work done by

Dr.LAKSHMI S. SUBEDAR in partial fulfilment for

M.D. (TUBERCULOSIS & RESPIRATORY MEDICINE) Examination

of the Tamil Nadu Dr. M. G .R. Medical University to be held in April 2018.

The period of study is from October 2016 to July 2017.

Dr. R. SRIDHAR M.D, DTRD,
Professor & Head of the Department,
Department of Tuberculosis
& Respiratory Medicine,
Stanley Medical College,
Chennai - 600001

Dr. PONNAMBALAM NAMASIVAYAM
MD. DA
Dean
Stanley medical college
Chennai - 600001

CERTIFICATE BY GUIDE

This is to certify that the dissertation on

"ELEVATED BLOOD EOSINOPHILS & SERUM IgE LEVELS AS BIOMARKERS IN PREDICTION OF COPD EXACERBATION"

is a record of research work done by

Dr. LAKSHMI S. SUBEDAR in partial fulfilment for

M.D. (TUBERCULOSIS & RESPIRATORY MEDICINE) Examination

of the Tamil Nadu, Dr. M. G .R. Medical University to be held in April 2018.The period of study is from October 2016 to July 2017.

DR.R.SRIDHAR,

M.D, DTRD,

Professor & Head of the Department,

Department of Tuberculosis & Respiratory Medicine,

Stanley medical college,

Chennai - 600001

DECLARATION

I hereby declare that the dissertation entitled

"**ELEVATED BLOOD EOSINOPHILS & SERUM IgE LEVELS AS BIOMARKERS IN COPD EXACERBATION"**

submitted for the Degree of Doctor of Medicine in M.D., Degree Examination, Branch XVII, TUBERCULOSIS & RESPIRATORY MEDICINE is my original work and the dissertation has not formed the basis for the award of any degree, diploma, associate ship, fellowship or similar other titles. It had not been submitted to any other university or Institution for the award of any degree or diploma.

Place: Chennai

Date: 20/10/17

Signature of the Scholar

(Dr. LAKSHMI S. SUBEDAR)

ACKNOWLEDGEMENT

Language with all elaborations seems to be having limitation especially when it comes to expression of feelings. It is not possible to convey it in words all the emotions and feelings one wants to say. It would take pages to acknowledge everyone who, in one way or another has provided me with assistance, but certain individuals deserve citation for their invaluable help.

I would like to express my heartfelt thanks to

Dr. PONNAMBALAM NAMASIVAYAM MD,DA Dean, Stanley Medical College and Hospital for giving me permission to conduct this study.

I fall short of words to express my deep sense of gratitude for my esteemed and reverend teacher, my chief **Prof. Dr. R. SRIDHAR, M.D, D.T.R.D,**
Head of the Department, Dept. of Tuberculosis & Respiratory Medicine,
Stanley Medical College and Superintendent, Govt. Hospital of Thoracic Medicine,
Tambaram Sanatorium, for his ever-inspiring guidance and personal supervision.
The finest privilege in my professional career has been the opportunity to work under his inspirational guidance.

I would like to thank my eminent teacher,

Associate professor Dr.V.VINOD KUMAR M.D, (CHEST), DNB. Who has been a guiding light with his constant encouragement throughout my post graduation course. I am honoured to have got an opportunity to be his student during my tenure at this prestigious institute.

I would like to express my sincere thanks and heartful gratitude to Associate professor DR.D.NANCY GLORY M.D., for her constant support and valuable guidance throughout my work.

I would like to thank my teachers in our department, who helped me in my work Dr.S.Kumar M.D, Dr. S.P.Vengadakrishnaraj D.T.C.D,DNB, Dr.K.Maheswaran M.D. I express my thanks to all the assistants in our department for their support.

I heartfully thank my seniors and junior colleagues for their involvement for completing this study.

I express my heartfelt gratitude to my father Mr. SUBHAS SUBEDAR and my mother Mrs. BHARTI SUBEDAR who always supported me throughout my carrier, guided me to solve my problems and stood beside my me in all my good and bad times. Their love, affection and support enabled me to reach this stage of life. This work is dedicated to my beloved father who dedicated his entire life for the wellbeing of me and my family..

I will always be grateful to my dear brother GANESH SUBEDAR for being cooperative, for sharing my enthusiasm and dismay and constantly supporting my ambitions and struggle. This work would not have been possible without his support in my difficult times.

Last but definitely not the least, I would like to thank my patients who cooperated with me throughout my work. Finally it is endowment of spiritualism and remembrance of almighty for all that I achieved.

- Dr LAKSHMI S SUBEDAR

CONTENTS

ABSTRACT

BLOOD EOSINOPHILS AND SERUM IgE LEVELS AS BIOMARKERS IN RESPONSE TO INHALED CORTICOSTEROIDS IN COPD

BACKGROUND:

Airway eosinophilia, hallmark feature of Asthma, is now a recognized inflammatory pattern in COPD. In 10–40% of COPD, eosinophilic airway inflammation has been reported.
Smoking (nicotine), a risk factor promotes allergic reactions which cause elevated IgE levels.

OBJECTIVES:

1.To identify COPD exacerbations associated with elevated blood eosinophils
2.To correlate elevated blood eosinophils and serum IgE levels with exacerbation of COPD

METHODOLOGY:

140 COPD patients were studied prospectively for a period of 1 year (Aug 2016 to Aug 2017) in GHTM, Tambaram. Patients with clinical diagnosis of COPD and post-bronchodilator FEV_1/FVC ratio of less than 0.7 as per GOLD criteria considered. Based on ANTHONISEN'S criteria classified as stable COPD & COPD exacerbation. Peripheral blood collected for Absolute Eosinophil Count (AEC) & Serum IgE.

RESULTS:

Among 140 COPD patients, Males-119(85%), Females-21(15%) were between 45-75 years of age group. COPD population belonging to GOLD I,GOLD II,GOLD III,GOLD IV staging were 21(15%), 40(28.5%), 58(41.4%), 21(15%) respectively. Of which, stable COPD were 53 (37.8%) & COPD exacerbations 87(62%). The AEC in stable COPD (468.9) & COPD exacerbation (890.8) while, Serum IgE in stable COPD (1289.5) & COPD exacerbation (2309) was observed. Current smokers showed elevated AEC (747) & Serum IgE levels (2214) compared to nonsmokers with AEC (660) & Serum IgE (646) respectively.

CONCLUSION:

AEC & Serum IgE levels can be considered as biomarkers of COPD exacerbations that allow identification of patients who most likely respond to ICS.

INTRODUCTION

COPD:

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death worldwide. By the year 2020, COPD is predicted to become the third leading cause of death worldwide [1].

In 10–40 %of COPD cases, eosinophilic airway inflammation has been reported during both stable disease and exacerbations. Recently, peripheral blood eosinophil counts can help in predicting the COPD exacerbations.

Chronic obstructive pulmonary disease (COPD) comprises of two diseases namely chronic bronchitis and emphysema. Chronic bronchitis is defined as "daily productive cough for at least three consecutive months for more than two successive years" [1, 2].

In 1962, American Thoracic Society (ATS) defined emphysema as an "anatomic alteration of the lung characterized by an abnormal enlargement of the air spaces distal to the terminal, non-respiratory bronchiole, accompanied by destructive changes of the alveolar walls"[3] .

In 1984, the National Heart, Lung and Blood Institute defined emphysema as "a condition of the lung characterized by abnormal, permanent enlargement of airspaces distal to the terminal bronchiole, accompanied by the destruction of their walls, and without obvious fibrosis"[4]. McDonough et al have reported that "the permanent enlargement of the distal airspaces may serve only as a structural biomarker, being a secondary result of small airway inflammation and destruction"[5] . This shows that in COPD, not only airway abnormality is present but also airspace abnormality is present.

PREVALENCE:

In COPD, prevalence rates vary considerably depending on the methods used for the diagnosis and classification.

COPD usually occurs after the age of 40 years. Incidence of COPD increases with an increase in age. The following chart shows that as the age advances, the prevalence rate also increase.

CHART 1:



The global prevalence of COPD is approximately 9-10 per cent[6].

According to INSEARCH study, in India, COPD prevalence among men is 9.02 million and among women is 5.75 million.[7]

DEFINITION OF COPD:

"COPD, a common preventable and treatable disease, is characterized by persistent respiratory symptoms & airflow limitation that is due to airway and/or alveolar abnormalities caused by the significant exposure to noxious particles & gases.[8]

RISK FACTORS FOR COPD:

Smoking:

Tobacco smoking is the most common risk factor for developing COPD[9]. A Swedish cohort study [10] and Denmark study [11] reported that population attributable risk for development of COPD in smokers respectively as 76.2% and 74.6%. In India most of them are using bidi for smoking than cigarette[12]. Ventilatory function deterioration is common among smokers than non-smokers. .

In males, average decline in FEV1 is approximately around 9 ml per year for each pack-year of smoking. In females average decline in FEV1 is approximately around 6 ml per year for each pack-year of smoking. Though tobacco content is low in bidi, bidi smokers are more vulnerable to develop COPD than cigarette smokers.[13]

Risk of COPD is directly proportional to the number of cigarettes or bidis smoked per day. Risk also increases with increase in duration of smoking. The risks are lower at a lower dose and lesser duration of smoking .The Lung Health Study found that there is an accelerated decline in FEV1 in COPD patients if they continue smoking.[14]

Environmental Tobacco Smoke:

ETS exposure is an important risk factor for developing COPD among nonsmokers especially women and children.

Occupational Exposure:

Chronic inhalation of particles and gases carry a greater risk for COPD. But we are not able to estimate the correct prevalence of COPD among workers because most of the workers are smokers and those with COPD drop out from work. The American Thoracic Society states that 15% of COPD cases are due to occupational exposure.

People working in rubber industry,plastic industry,leather industry are at increased risk of COPD.[19] Also, people who work in textile mills and food product manufacturing are also at increased risk.[15]

Outdoor Air Pollution:

In developing countries like India, especially in urban population, outdoor air pollution has been implicated as a cause for COPD and various other respiratory diseases[16.] It is due to pollutants from industries and motor vehicles causing pathological changes in lung and airway. A previous study observed that higher traffic density is associated with increased risk of COPD in women. These pollutants may cause bronchial hyperactivity, airway oxidative stress, pulmonary and systemic inflammation[17].

Indoor Air Pollution:

Biomass fuel is obtained from the combustion of dried dung, wood, and crop residue. Exposure to biomass fuel is an important source of indoor air pollution. It is an important cause of COPD among women especially in rural India. Combustion of biomass fuel in closed spaces results in the inhalation of the toxic gases which contributes to the development of COPD. The risk of COPD among women in urban areas is less when compared to women in rural areas. This is because women in rural areas use biomass fuel whereas women in urban areas use LPG as fuel for cooking purposes.

Alfa-1 Antitrypsin Deficiency:

It accounts for around 1-2% of total cases of COPD.

Conditions suggesting alpha 1 anti-trypsin deficiency:

1. Early onset emphysema (age less than 45 years).

2. Emphysema in a non-smoker.

3. Emphysema predominantly in lung bases.

4. Family history of early onset emphysema or non-smoking related emphysema.

5. Bronchiectasis without any other aetiology[8].

Childhood Lower Respiratory Tract Infections:

Ventilatory function in adults depends on the lung function in their childhood days. Hence, lower respiratory tract infections during childhood that affect lung development, tend to increase the risk of developing COPD later in life.[18]

Genetic Factors:

Polymorphisms of genes involved in protease- antiprotease balance, antioxidant function, inflammation, and immune responses have been implicated in COPD.

In one study, a combination of both candidate gene and positional cloning approaches were used. Boston Early-Onset COPD study evaluated a single nucleotide polymorphism (SNPs) in and around the transforming growth factor-β1 (TGF-β1) region located in chromosome 19q and found that it was linked to prebronchodilator FEV1in smokers[8].

Airway Hyperresposiveness:

In COPD, airway hyper-responsiveness is associated with accelerated decline in FEV1.However airway hyper-responsiveness does not predict bronchodilator responsiveness.

Other Miscellaneous Factors:

Low socioeconomic status, advancing age are some of the factors associated with increased risk of COPD. This is because, an increased amount of smoking is seen in people with low socioeconomic status. Also, old age people receive deficient medical care.

PATHOGENESIS:

a) Inflammation:

Inflammation of the lower respiratory tract plays an important role in pathogenesis of COPD. Following the exposure to tobacco smoke and other inhaled particles, there is a recruitment of inflammatory cells in the lungs and airways. These inflammatory cells are neutrophils, eosinophils, macrophages and lymphocytes. They cause lung injury and disrupt the normal mechanism of lung repair. Bronchoalveolar lavage (BAL) fluid collected from smokers contain more macrophages when compared to non smokers[8].

Fig.2 : Basic view of COPD pathology



Fig. 3 : Overview of Pathogenesis in COPD.



b) Proteinase and Antiprotease Imbalance:

In COPD, there is an imbalance in the production of proteinase and antiproteinase. Major proteinase that affect lung parenchyma are neutrophil elastase, Proteinase 3, cathepsin B, cathepsin L, cathepsin S, MMP (Matrix Metalloproteinase).Some of the antiproteinases are alfa 1 antitrypsin,Matrixmetalloproteinase inhibitors, alfa 2 macroglobulin, Secretory leukocyte protease inhibitor(SLPI), Elafin and cystatin C. Neutrophil elastase causes parenchymal destruction, mucous gland hyperplasia and induces mucus secretion.

c) Oxidative Stress

Cigarette smoke contains many chemicals that are highly reactive oxidant species. Also, the inflammation itself generates oxygen-free radicals leading to tissue damage. In vitro study done by Schaberg et al showed that airway neutrophils and alveolar macrophages generate more oxygen free radicals such as hydrogen peroxide, hydroxyl radicals, and superoxide radicals in smokers than non-smokers.

Oxidative stress causes the damage of extracellular matrix and inactivation of key anti-oxidant defences. Antioxidants give protection against oxidative injury. Superoxide dismutase, Catalase, and glutathione peroxidase are some of the antioxidants that give protection against oxidation injury. Copper and zinc dependent superoxide dismutase are found in cytoplasm whereas manganese dependent superoxide dismutase is found in mitochondria.

Vitamin A and VitaminE are present in epithelial lining fluid. They also act as antioxidants[8].

Elastase-Antielastase Hypothesis:

Lung Elastic Fiber

Destruction of lung elastic fibres plays a key role in the development of emphysema. Extracellular matrix of lung parenchyma is organized as

1.axial system 2.parenchymalsystem 3.peripheral system.

Axial system extends from central airway to alveolar ducts. Parenchymal system is formed by matrix of alveolar septae. Peripheral system arises from visceral pleura and extends into alveolar septae. Distal to respiratory bronchiole, axial system forms helix encircling alveolar duct. Elastin is the main component of axial system and these elastic fibres provide elastic recoil throughout respiratory cycle. Elastin is resistant to many proteinases, however many enzymes are capable of degrading elastin such as neutrophils elastase, proteinases 3, cathepsin G, MMP-9, MMP-12, cathepsin L and cathepsin S.

Fig.4: Changes at alveolar level in COPD



During COPD exacerbations, inflammation in the airways increases. While this inflammation in patients with COPD is primarily neutrophilic, in some patients it is associated with an increased sputum eosinophil count of more than 3%. Neutrophilic airway inflammation appears to be poorly responsive to corticosteroid treatment , and the absence of bacterial inflammation may therefore favour a greater corticosteroid response.

Airway eosinophilia, a hallmark feature of asthma, is now a recognized inflammatory pattern in chronic obstructive pulmonary disease (COPD) & COPD is a heterogeneous disease for which there are limited choices with respect to therapeutic mechanisms of action.

REVIEW OF LITERATURE

COPD:

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death worldwide by the year 2020, COPD is predicted to become the third leading cause of death worldwide (exceeded only by heart disease and stroke)

COPD is defined as common, preventable and treatable disease which is characterised by persistent respiratory symptoms and aiflow limitation due to airway and /or alveolar abnormalities usually caused by the significant exposure to noxious particles and gases. smoking being the primary risk factor for the development of COPD.

COPD exacerbation is defined as acute worsening of respiratory symptoms that result in additional therapy. COPD exacerbations are associated with poor quality of life as well as increased morbidity and mortality which are classified as mild, moderate and severe.

Mild exacerbation - treated with short acting bronchodilators only

Moderate exacerbation – treated with short acting bronchodilators/oral corticosteroids with antibiotics.

Severe exacerbation - requires hospitalization [8,19]

PREVALENCE:

Prevalence of ACOS in the asthma/COPD population ranged between 4.4% and 38.3%, depending on the definition used. Asthma and COPD are prevalent chronic inflammatory airway diseases that are responsible for a large global disease burden. Both diseases are complex and heterogeneous, and they are increasingly recognized as overlapping syndromes that may share similar pathophysiologic mechanisms and treatable traits[20].

ASTHMA, COPD, ACOS:

Patients with the asthma–COPD overlap syndrome (ACOS) have a more rapid disease progression, more respiratory symptoms, exacerbations, comorbidities and healthcare utilisation, compared to subjects with either disease alone.

According to some authors, ACOS is a syndrome in which older adults, generally with a significant history of smoking, have a partially reversible or fixed airflow obstruction and evidence of atopy or asthma. ACOS represents a form of severe asthma, characterized by more frequent exacerbations, and it is likely to be the result of early asthma that has progressed to fixed airflow obstruction, possibly because of airway remodelling. It is still an open question whether ACOS is the result of asthma that has progressed to fixed airflow obstruction, or the expression of COPD in patients with airway hyperresponsiveness or a specific disease entity[21].

One explanation is that the mechanisms and pathways of airflow obstruction in ACOS and COPD may be different. Asthma and COPD are highly complex, many different inflammatory cells and multiple mediators with complex acute and chronic effects on the airways are part of the syndromes. Many different inflammatory cells are involved in asthma, although the precise role of each cell type is not yet certain. The inflammation in asthmatics airways differs strikingly from that observed in COPD, where there is a predominance of macrophages, cytotoxic (CD8+), lymphocytes, and neutrophils, although both these common diseases may coexist in some patients.

Chronic airflow obstruction was defined as a pre-bronchodilator FEV_1/FVC<lower limit of normal both at baseline and at follow-up. Transient airflow obstruction was defined as a FEV_1/FVC<lower limit of normal at baseline but not at follow-up. Airway hyperresponsiveness was defined as a decrease of 20% in FEV_1 after a cumulative methacholine dose $\leq$1 mg.

Exacerbations of asthma often have identifiable triggers such as allergens, cold air, or exercise. However, exacerbations in COPD patients are commonly caused by respiratory tract infections. But, different clinical exacerbation phenotypes, can be observed. Two of which are the bacterial and eosinophilic exacerbation phenotypes. During COPD exacerbations, inflammation in the airways increases. While this inflammation in patients with COPD is primarily neutrophilic, in some patients it is associated with an increased sputum eosinophil count of more than 3%. Neutrophilic airway inflammation appears to be poorly responsive to corticosteroid treatment , and the absence of bacterial inflammation may therefore favour a greater corticosteroid

response through a shift in the balance of airway inflammation away from neutrophilic inflammation towards more eosinophilic inflammation.

EOSINOPHILC INFLAMMATION:

Airway eosinophilia, a hallmark feature of asthma, is now a recognized inflammatory pattern in chronic obstructive pulmonary disease (COPD) & Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease for which there are limited choices with respect to therapeutic mechanisms of action.

Eosinophils are innate immune cells that, under certain conditions, can be recruited to the lungs, where they have an incompletely understood role in health and disease. Eosinophils are granulocytes derived from common myeloid progenitors in the bone marrow. The maturation of eosinophil progenitors depends largely on cytokines such as IL-3, IL-5, and granulocyte macrophage-colony stimulating factor. Of these cytokines, IL-5 is the most critical for eosinophil proliferation, differentiation, and activation. Under normal circumstances, eosinophils constitute only 1% to 2% of the total WBC pool. Eosinophils have been found in the airways, tissues, and circulation of patients with COPD, during both stable disease and exacerbations. Evidence suggests that eosinophilic airway inflammation is important in the pathogenesis of severe chronic obstructive pulmonary disease (COPD) exacerbations.

In 10–40% of COPD cases, eosinophilic airway inflammation has been reported during both stable disease and exacerbations. ECLIPSE (Evaluation of COPD

Longitudinally to Identify Predictive Surrogate Endpoints) study cohort, only 37% of the patients with COPD had persistently increased blood eosinophils at or above 2%.

SPUTUM & BLOOD EOSINOPHILS:

Sputum and blood eosinophil counts have attracted attention as potential biomarkers in chronic obstructive pulmonary disease (COPD) during exacerbations. Increased numbers of eosinophils have been detected both in induced sputum and in bronchial biopsies, whilst blood eosinophilia has been associated with increased mortality in COPD .Sputum eosinophilia occurs in approximately one-third of stable chronic obstructive pulmonary disease (COPD) patients. The detection and measurement of airway eosinophilia mostly require the assessment of induced sputum[22].

Although, sputum induction is considered a direct and reliable method of assessing airway inflammation with an increased sputum eosinophil count of more than 3%, it had limitations. Therefore, Blood eosinophils is considered to be more easily accessible biomarker of eosinophilic airway inflammation compared to the induced sputum. Blood is a simple predictor of more lung eosinophils compared to sputum eosinophils[23].

In COPD, there is a fair correlation between blood and sputum eosinophil counts with a differential count of 2% or higher in blood and a positive predictive value of 90% for an increased sputum eosinophil count. For blood eosinophils, a cut-off level of 2% was used, as this shows high sensitivity for predicting sputum eosinophilia.

Although blood eosinophil counts in absolute number and as a percentage of the leukocytes are close to being the same, using an alternative blood eosinophil cut-off level (absolute numbers ≥300 μl) showed a similar pattern of differences to the 2% eosinophil cut-off. The correlation between eosinophil absolute numbers and percentages was strong ($\rho=0.92$; $p<0.001$), with 88% concordance between samples classified using 2% and 300 μl cut-off values.

The increase in exacerbation rate became more pronounced as the eosinophil cut-off level rose, with significant treatment-by-subgroup interaction reached for 4% and 5% only.

Peripheral blood eosinophil counts can help identify the presence or absence of sputum eosinophilia in COPD patients with a reasonable degree of accuracy. The use of peripheral blood cell counts as a potential alternative. Peripheral blood eosinophils can serve as a promising surrogate marker for sputum eosinophilia in COPD.

Furthermore, among the individuals with higher levels of eosinophils, a higher percentage experienced wheezing during a cold and reported sputum of 3 months duration with history of respiratory infections. They also had higher degrees of airflow limitation & increased length of hospital stay. Fewer individuals with eosinophils above 2% were current smokers, but the groups did not differ in pack-years of smoking. Likewise, more men than women with COPD had eosinophils of 2% or higher. Patients with blood eosinophilia had a higher postbronchodilator FEV1% predicted and a lower bode index score compared to those without (0.4×109/l).percentage of the individuals with eosinophils above 2% had occupational

exposure to dust and fumes and exacerbation rates increased progressively with increasing eosinophil counts. Recent evidence has shown that elevated blood eosinophil counts in severe COPD exacerbations are associated with a > 3-fold increase in readmission rate.

SPUTUM EOSINOPHILS & BACTERIAL LOAD:

Some studies have showed an inverse relationship between sputum eosinophils and airway bacterial load during the stable state, while a decrease in blood eosinophil counts occurs in COPD exacerbations with bacterial presence. The existence of such an inverse relationship would suggest that the interaction between bacterial infection and eosinophils determines the corticosteroid response in COPD patients[24]. Using 2% baseline eosinophil count as a threshold, patients with COPD with lower blood eosinophil counts had more pneumonia events than did those with higher counts. These inverse relationships between eosinophil measurements and bacterial counts are potentially important determinants of individual responses to corticosteroid treatment[25].

Conditions causing elevated blood eosinophils:

1. Parasitic infections – Ascariasis, Strongyloidosis
2. Fungal infections
3. Allergies including allergies to medications
4. Allergy to food substances

5. Skin disorders - atopic dermatitis
6. Automimmune diseases
7. Malignancy - acute myeloid leukemia
8. Asthma
9. Churg strauss syndrome
10. Chron's disease
11. Hypereosinophilic syndrome
12. Lymphatic filariasis
13. Ulcerative colitis

SERUM IGE:

The elevated total IgE is also another risk factor associated with COPD :

1. Smoking is a major risk factor for COPD, and nicotine promotes the development of allergic reactions which causes increase in IgE levels and sensibillisation to different allergens. IgE level of COPD patients was higher than normal range, which could be due to the degree of tobacco smoking, or local production of IgE in the bronchial mucosa[26].

2.The results demonstrated that the prevalence of elevated serum IgE in patients with COPD, implying that even among COPD patients without obvious atopy, hypersensitive inflammation of the lower airways may exist, probably representing the real proportion of the allergic phenotype in patients with COPD.

3. Blood group "A", suggesting genetically caused increased synthesis in serum IgE.

The increased serum total IgE is a sensitive marker for allergy. Study suggests that in COPD, serum IgE levels correlate with clinical aspects of disease severity[27].

COPD patients with higher smoking index had earlier onset of dyspnoea on a background of chronic cough /sputum, longer duration of illness, more severe lung function impairment, more with patient with repeated frequent exacerbation.

Variations in the upper limit of normal total serum IgE have been reported: they can range from 150 to 1,000 UI /ml; but the usually accepted upper limit is between 150 and 300 UI/ml.

Conditions causing elevated serum IgE:

1. Parasitic infections
2. Bronchial asthma
3. Allergic bronchopulmonary aspergillosis
4. Churg strauss syndrome
5. Hyper – IgE syndrome

Hyper IgE Syndrome (HIES) is a rare primary immunodeficiency disease characterized by eczema, recurrent staphylococcal skin abscesses, recurrent lung infections, eosinophilia (a high number of eosinophils in the blood) and high serum levels of IgE. Most cases of HIES are sporadic, but some familial cases of HIES have been reported, with either an autosomal dominant (AD) or autosomal recessive (AR) mode of inheritance.

Definition of Hyper IgE Syndrome:

HIES is a rare primary immunodeficiency characterized by recurrent eczema, skin abscesses, lung infections, eosinophilia and high serum levels of IgE. Two form of HIES have been described, including an autosomal dominant (AD, or type 1) and an autosomal recessive (AR, or type 2) form. These two forms share overlapping clinical and laboratory features including eczema, recurrent infections, skin abscesses, high IgE level and increased eosinophil number. However, they also exhibit distinct clinical manifestations, courses and outcomes.

OTHERS BIOMARKERS IN COPD:

Others such as - Fibrinogen, adiponectin, sp-d and cc-16, β-defensin-2, cxcl7(chemokine (c-x-c motif) ligand 7), leptin and mmp-8 (matrix metalloproteinase 8), cxcl10, ccl2, crp can also be used as blood biomarkers to assess the response to therapy in COPD. The most stable biomarker over 3 months in the eclipse biomarker cohort was fibrinogen. It was significantly elevated in COPD patients relative to both ex-smoking and non-smoking controls.

Fig 6: systemic inflammation in COPD:



MANIFESTATIONS OF COPD:

EMPHYSEMA:

Fig.7: Types of Emphysema



Centrilobular Emphysema

In Centrilobular emphysema, pores of kohn is the initial site of destruction. The respiratory bronchioles appears dilated and enlarged. The alveolar duct and alveoli appears normal. Centrilobular emphysema commonly affects upper zone. Most affected segments are apical & posterior segments of upper lobe. In severe cases, the destruction may proceed towards the periphery of the lobule, so that distinction between centrilobular and paraseptal emphysema becomes blurred.

Panlobular Emphysema

Lower lobe is affected predominantly in panlobular emphysema. Alveolar duct and alveoli distinction is lost. The sharp angles of alveoli are also lost. The pores of Kohn are more uniform and inconspicuous when compared to centrilobular emphysema. Mild panlobular emphysema is difficult to diagnose.

Pan lobular emphysema is most commonly seen in patients with alpha1 antitrypsin deficiency, constrictive bronchiolitis, and obliterative bronchiolitis.

Paraseptal Emphysema

More distal part of the acinus is affected like alveoli and alveolar duct. It is commonly seen adjacent to the pleura**,** along lobular septa and at the margins of lobules and acini.

Irregular Emphysema:

Irregular emphysema is adjacent to a scar, so it is otherwise called as paracicatricial emphysema. Most scars within lungs are small, so emphysema is limited in extent.

CHRONIC BRONCHITIS:

It is characterized by chronic cough and sputum production. Chronic mucus hypersecretion associated with airflow obstruction is called chronic obstructive bronchitis.

SMALL AIRWAY DISEASE:

The smaller conducting airways (< 2 mm in diameter) is a major site of airway obstruction in COPD [28]. Inflammation, fibrosis, luminal plugs occur in small airway leading to increased airway resistance.

CLINICAL FEATURES:

Dyspnoea is seldom a compliant until FEV1 falls below 60% of predicted. Assessment of dyspnea is done by MMRC dyspnoea scale.

The other symptoms are cough with expectoration and fever if there is acute exacerbation. Unable to do normal day to day activities, sleep disturbances.

Hyperinflation is common in moderate and severe COPD, it produces

1.Increase in residual volume

2.Increased ratio between residual volumes to total lung capacity.

Hyperinflation causes increase in dyspnoea by:

1. Decreased apposition between the muscles of abdomen and the diaphragmatic muscle.

2. Flattening of diaphragm causes increased radius of curvature, there by decrease in transpulmonary pressure.

3. Shorter diaphragm muscle fiber length causes decrease in the force of contraction.

During exercise, hyperinflation worsens because of airflow obstruction during expiration. HIV/AIDS is also associated with premature emphysema.

Lung volume measured by helium dilution method and nitrogen washout plethysmography shows elevated total lung capacity and residual capacity. The carbon monoxide diffusion capacity is decreased in patients who have an FEV1 less than 1.0 L

SIGNS:

Inspection[29]

Pursed-lip breathing

Barrel shaped chest

Filling of neck veins during expiration

Hoover sign

Short trachea

Pulsus paradoxus

Increased anteroposterior diameter of the chest (barrel-shaped chest)

Reduced chest movements

Peripheral edema

Muscle Wasting

Palpation: Reduction in the expansion of the chest.

Percussion: Tympanic note heard due to hyperinflation of the lung.

Auscultation: Decrease in respiratory sounds and expiration is prolonged, polyphonic wheeze during expiration.

CHEST X RAY FINDING:



Fig.7: Chest Xray PA view in COPD:

1. Increased radiolucency.
2. Bilateral hyperinflation.
3. Decreased peripheral blood vessel shadows.
4. Flattening of diaphragm.
5. Decreased cardio-thoracic ratio- cardiac diameter less than 11.5cm with vertical heart and lung seen below the heart.
6. Increased intercostal space

Fig.8: Chest X-ray lateral view in COPD



1. Increase in retro cardiac space.
2. Increased in retrosternal area- measurement taken between anterior aspect of ascending aorta and the posterior aspect of sternum 3 cm below manubriosternal joint.
3. Obtuse costophrenic angle.

HRCT lung:

Centrilobular Emphysema: In this type there is an ill-defined margin with areas of low attenuation area. In early stage of COPD, upper zone of lung is usually affected with low attenuated areas closely related to centrilobular arteries. Lung surrounding the low attenuated area appears normal.

Panacinar Emphysema: Lung destruction is uniform and gives rise to generalize low attenuation density of lung. Panacinar emphysema affects the lower lobe predominantly.

Paraseptal Emphysema: Sub pleural well-marginated low attenuation area with distinct hairline walls are seen. This pattern resembles saw teeth appearance.

Emphysema can be assessed by using lung density index. Gevenios et a study among COPD patients showed density of -950 HU providing an accurate estimation of COPD.

Fig.9: HRCT picture in a upper lobe emphysema



Goddard classification of COPD [30]

1 point: scattered emphysematous lesion 1 cm or less in diameter.

2 point: large size Low Attenuation Area (LAA) due to the fusion of emphysematous lesions.

3 point: LAA occupies an even larger area by the more pronounced fusion.

4 point: most of the lung occupied by emphysema and only a small area of normal lung.

Visual evaluation of pulmonary emphysema[31]

Right and left lung are divided into six areas namely upper, middle, and lower lung fields on both sides. Degree of severity of pulmonary emphysema is graded based on five-point scale

0 point: no emphysematous lesions.

1 point: occupies less than 25 % of the entire lung field.

2 point: occupying from 25% to less than 50% of the entire lung field.

3 point: occupying from 50% to less than 75% of the entire lung field.

4 point: occupying more than 75 % of the entire lung field.

Maximum total = 24 points.

Spirometric assessment:

Spirometry is essential for diagnosis of COPD. It is also useful for classification of severity and assessing the progression of the disease. For the diagnosis, post bronchodilator FEV1/FVC should be less than 0.70. The severity of the disease is based on the FEV1.

Table 4: Classification Of Severity Of Airflow Limitation In COPD.

Category/Severity Stage	FEV_1/FEV	FEV_1 (% Predicted)
Normal (healthy patients)	0.80	~100
I: Mild	<0.70	≥80
II: Moderate	<0.70	50 to <80
III: Severe	<0.70	30 to <50
IV: Very Severe	<0.70	<30[a]

COMORBIDITIES ASSOCIATED WITH COPD PATIENTS:

Because of common risk factors, COPD patients will have more number of comorbidities like cardiovascular disease, atherosclerosis, hypertension, depression, pulmonary embolism and lung cancer. Comorbidity occurrence is independent of severity of airflow limitation which can occur at any stage of the disease.

THERAPEUTIC OPTIONS AVAILABLE:

Smoking Cessation:

Since Smoking is a major risk factor for the development of COPD, cessation of smoking is the main aim to prevent COPD. Health care professional should provide information regarding smoking cessation messages.

Behavioural approaches:

The clinicians can use the following method while counselling the patients on. Popularly referred as “the five A’s”---

ASK (about tobacco use)

ASSESS (the status and severity of use)

ADVICE (to stop)

ASSIST (in smoking cessation)

ARRANGE (follow-up program)

Group counselling:

These programs include lectures on pathophysiology of smoking, ill effects of smoking, consequences of smoking habit, group interactions and exercises.

Success rate is in the range of 15-35% at the end of 1 year. These programs are run by several commercial and voluntary health organizations.

Gradual reduction vs abrupt abstinence:

In gradual reduction phase patients experience tobacco withdrawal symptom when their nicotine level falls below critical threshold level. They may also experience prolonged discomfort. So many people gradually return to their previous cigarette smoking level.

In Abrupt abstinence also, patients experience tobacco withdrawal symptoms. But craving for cigarette is less than gradual taperers. Also, the relapse rate is less.

Pharmacotherapy for Smoking Cessation

• Three classes of agents approved

– Nicotine replacement

– Bupropion

– Varenicline

• Secondary agents (off label agents) used

– Clonidine

- Nortriptyline

Nicotine replacement therapies:

• Five nicotine replacement therapies approved

• Available as OTC (over the counter)

– Lozenges

– Gum (polacrilex)

– Transdermal patches

• Available with a prescription

– Nasal spray

– Nicotine inhaler

• Others

– Toothpicks and E-cigarettes

THERAPEUTIC OPTIONS:

The Pharmacological class of drugs that are available for the treatment of COPD are given below.

COPD Medications

1. Beta2-agonists

    Short-acting beta2-agonists

    Long-acting beta2-agonists

2. Anticholinergics

Short-acting anticholinergics

Long-acting anticholinergics

Combination short-acting beta2-agonists + anticholinergic in one inhaler

Combination long-acting beta2-agonist + anticholinergic in one inhaler

3. Methylxanthines

4. Inhaled corticosteroids

5. Combination long-acting beta2-agonists + corticosteroids in one inhaler

6. Systemic corticosteroids

7. Phosphodiesterase-4 inhibitors

8. Molecular biomarkers

Bronchodilators:

Bronchodilators will improve the FEV1 by modifying tone of the airway smooth muscles. It widens the airway and thereby increases the expiratory flow .It also reduces dynamic hyperinflation during exercise and rest. Toxicity is dose related. Inhaler therapy is preferred, in which long acting bronchodilator is more efficacious than short acting drugs. Bronchodilators play central role in symptomatic management in COPD patients. Combination of different classes of bronchodilator drugs will improve efficacy and decrease the adverse effects.

Anti-cholinergic drugs:

Most commonly used drugs are ipratropium, oxitropium, Tiotropium.

These drugs block the acetylcholine and act on muscarinic receptors. Short acting drugs block M2, M3 receptors and pre-ganglionic junctional transmission is modified. Long acting drugs block M3 and M1 receptors. Anti-cholinergic drugs act longer duration than beta2 agonists. Those with short action have 8 hours of bronchodilator activity and long acting has 12 hours of action

Beta2 agonist:

Beta2agonist causes relaxation of smooth muscle present in the airway mediated via beta2 receptors, causing increased CAMP. Short acting bronchodilators usually have 4 to 6 hours of action, long acting drugs have action of 12 or more hours. To improve the compliance of treatment long acting drugs are used once daily in the treatment of COPD. Study conducted by Gregory

Feldman shows 150 micro gram of once daily Indacaterol is more compliant for the patients as well as less number of drop out. The only long acting beta agonist which has 24 hours of action is Indacaterol.

SABA- (Short Acting Beta Agonist)- e.g- Salbutamol.

LABA- (Long Acting Beta Agonist) - e.g- Salmetrol, Formetrol & Indacaterol.

A study was done by James et al in COPD patients for comparison of Tiotropium and Indacaterol on trough FEV1 after 12 weeks of treatment. It also evaluated safety and

efficacy after 26 weeks of treatment. They conclude that Indacaterol is more efficacious in bronchodilation and has higher compliance than Tiotropium and placebo.

Adverse effects:

1. Sinus tachycardia, and precipitate cardiac disturbance in some patients.

2. Exaggerated somatic tremor.

3. Hypokalemia.

4. Tachyphylaxis.

Methylxanthines:

Xanthines act as non-selective phosphodiesterase inhibitors. Theophylline produces bronchodilation by blocking adenosine action. It improves the diaphragmatic muscle contraction, prevents respiratory muscle fatigue, increases ventilatory drive and potentiates catecholamine function.

Theophylline decreases cough by augmenting mucociliary clearance, reduces the late-phase antigen responses, suppresses leukocyte activation, and inhibits of mast cell histamine release.

Corticosteroids:

The role of Corticosteroids in reduction of pulmonary and systemic inflammation is controversial, so use of corticosteroid alone in management of stable COPD is not advised. But some study demonstrates that regular use of corticosteroid will produce improvement in lung function, reducing the frequency of exacerbation, improving symptom and quality of life especially in patients with more severe disease.

Adverse effects:

Commonly encountered adverse effects of corticosteroids are oral candidiasis, hoarseness of voice and skin bruising, Long term treatment is associated with pneumonia, osteopenia, and osteoporosis

Phosphodiesterase IV inhibitors:

Roflumilast is a phospodiesterase-4 inhibitor. It reduces exacerbations in patients with severe and very severe COPD and also in patients with chronic bronchitis. Eosinophilic airway inflammation is a key “treatable trait” in patients with chronic airway diseases, including asthma and COPD.

Stratification of patients according to markers of eosinophilic airway inflammation has led to the identification of patients at risk of adverse outcomes and treatment guided by markers of eosinophilic airway inflammation has resulted in better health outcomes. However, many patients, in particular adults with severe disease, have persistent eosinophilic airway inflammation. These patients experience frequent

exacerbations, and they often depend on the chronic use of oral corticosteroids with associated serious adverse effects. Not surprisingly, targeting eosinophilic airway inflammation has been the basis of recent new drug development.

Researchers in various studies have found that increased sputum eosinophil counts are associated with a favourable response to both inhaled and systemic corticosteroids and that reducing sputum eosinophil counts also reduces the risk of severe exacerbations respiratory infections.

Also, found that patients with COPD with high levels of blood eosinophils had a greater reduction in exacerbation rates than patients with low levels of blood eosinophils when treated with an inhaled corticosteroid

As well as being useful in guiding corticosteroid treatment, recent studies also suggest eosinophil count may be useful for guiding combined inhaled corticosteroid and long-acting beta agonist (ICS/LABA) therapy

Furthermore, corticosteroid treatment, which modulates eosinophilic airway inflammation but has a less clear effect on neutrophilic airway inflammation, is effective in the treatment and prevention of COPD exacerbations[32].

Clinical trials of corticosteroid treatment for COPD have shown that the blood eosinophil count is associated with the risk of COPD exacerbations, mortality, decline in fev_1, and response to both inhaled and systemic corticosteroids[32].

Eosinophilic airway inflammation is considered the most influential “treatable trait” of chronic airway disease, and over the last decade, several monoclonal antibodies and small molecule therapies have been developed to target this trait. These

include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin d_2 blockers (fevipiprant and timapiprant).

Although these novel biologic agents have shown promising results in many patients with asthma and COPD who have eosinophilic airway inflammation, it is evident that not all patients respond equally well, despite similar clinical, functional, and inflammatory characteristics. This heterogeneity in treatment response is probably related to different molecular pathways or endotypes leading to eosinophilic airway inflammation, including adaptive immune pathways mediated by T helper 2 cells and innate immune pathways mediated by innate lymphoid cells. The relative contribution of these pathways in asthma and COPD is not yet clarified, and there are currently no reliable biomarkers that represent the various pathways[33].

For patients exhibiting this trait who have an incomplete response to high doses of inhaled corticosteroids, novel monoclonal antibodies or small molecule therapies have been developed. These drugs have been shown to reduce disease exacerbations and to have an oral corticosteroid-sparing effect in many but not all of these patients. Unfortunately, for the practicing clinician, it is not yet clear which patients will respond to which biologic agents. Thus far, it seems that anti-IL -5 is most efficacious in patients with high blood eosinophil counts.

For anti-IL-5 treatment, blood eosinophil counts seem to be the best predictors of response, particularly in patients with adult-onset asthma but also in patients with COPD

Other Pharmacological Treatments:

Vaccines:

Vaccines are found useful in preventing exacerbations in COPD patients. Pneumococcal polysaccharide vaccine and influenza vaccine are the two vaccines commonly used in COPD patients. Influenza vaccines can reduce serious illness. Killed influenza vaccine is preferred over the live influenza vaccine.

Antibiotics:

The use of antibiotics is currently indicated only in cases of bacterial exacerbations.

Alpha-1 antitrypsin therapy:

Replacement with alfa-1 antitrypsin is considered in patients with severe deficiency.

Pulmonary Rehabilitation:

Pulmonary rehabilitation is defined as "an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. Integrated into the individualized treatment of the patient, pulmonary rehabilitation is designed to reduce symptoms, optimize functional status, increase participation, and reduce healthcare costs through stabilizing or reversing systemic manifestations of the disease"[34]

Long term oxygen therapy:

Supplemental oxygen is recommended in the following patients.

PaO2 of < 55 mmHg (or pulse oxygen saturation of < 88%), or

PaO2 56-60 mmHg (or pulse oxygen saturation of 88-92%) with evidence of end organ dysfunction including pulmonary hypertension, congestive cardiac failure, and erythrocytosis with haematocrit > 55%.

Also, hypoxia should be demonstrated on two occasions at least 3 weeks apart in the stable patient.

Non-invasive Ventilation:

The indications for NIV in stable COPD are:

1. PaCO2 ≥ 55 mmHg or PaCO2 of 50-54 mmHg and nocturnal desaturation (oxygen saturation by pulse oximeter ≤ 88% for continuous 5 min while receiving oxygen therapy at 2 L/min)
2. PaCO2 of 50-54 mmHg and hospitalization related to recurrent (≥ 2 in a 1 month period) episodes of hypercapnic respiratory failure[35].

BRONCHOSCOPIC TECHNIQUES IN STABLE COPD:

Non return endobronchial valves are popular for the treatment for bullae.

Lung volume reduction surgery (LVRS) is also done endoscopically by thermal vapour ablation technique.

SURGICAL TREATMENT FOR COPD:

Three primary surgical modalities are available.

1. Bullectomy

2. Lung volume reduction surgery (LVRS)

3. Lung Transplantation:

ACUTE EXACERBATION OF COPD:

An exacerbation of COPD is defined as "A sustained worsening of the patient's condition, from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD."

We should exclude other causes of worsening of symptoms like congestive cardiac failure, pneumothorax, and pulmonary embolism. Frequency and severity of acute exacerbation of COPD depends upon medication administration, smoking status, vaccination and disease severity.

Impact of acute exacerbation of COPD:

1. Acute exacerbation of COPD will produces short term and long term impact on health status, the additional decline in FEV1 averaged approximately about 7 to 8 mL/year.

2. Acute exacerbation of COPD is major source of health care expenditure, especially when patient is admitted for hospitalization.

3. Recurrent episodes of acute exacerbation will affect the health related quality of life. Following single episode HQOL(Health-related Quality Of Life) improves over 26 weeks, acute episode has negative impact on health related quality of life.

Also, the cost of treatment is an important factor particularly for the economically backward people.

On serial CT scan imaging, exacerbations are associated with progression of emphysema. Moreover, exacerbations lead to a decline in Quality of life and it causes an economic burden on the patient.

Precipitating factors for exacerbation34

1) Infectious (60-80% of all exacerbations)

a) Viruses like influenza, parainfluenza, rhinovirus and coronaviruses.

b) Bacteria - Hemophilus influenza

Steptococcus pneumonia

Moraxella catarrhalis

Pseudomonas aeruginosa

Opportunistic gram-negative species

Staphylococcus aureus

2) Environmental Factors

a) Cold air, allergens, tobacco smoke

b) Air Pollution- Both particulate and non-particulate matter for example sulphur dioxide, ozone, black smoke, and nitrogen dioxide causes acute exacerbation of COPD

3) Non-adherence to respiratory medication.

Evaluation of AE COPD:

Clinical evaluation is done to identify the cause for exacerbation, and to rule out other causes for exacerbation like congestive cardiac failure, pneumothorax, and pulmonary embolism. These conditions also produce dyspnoea.

Hence it is necessary to rule out these conditions.

Pathophysiology of acute exacerbation of COPD:

The factors that favours acute respiratory Failure development during AECOPD depends on following:

a) Severity of precipitating cause,

b) Degree of physiological dysfunction,

c) Subsequent physiological reserve.

Investigations:

1. Chest X ray:
2. It is used to rule out other causes for exacerbation like parenchymal infiltration, pneumothorax, pleural effusion, cardiomegaly with pulmonary congestion and pulmonary embolism.
3. ECG is done to rule out cardiac problems.
4. Arterial blood gas analysis is used for assessment of oxygen status, carbondioxide level and pH of blood to decide about treatment.

5. Sputum cultures are useful in the identification of organism that is responsible for exacerbation.

Management:

At home:

Most patients can be managed at home. Increasing the frequency of inhaled SABA for several days is effective in mild exacerbations. If patient develops severe dyspnoea and if he develops change in the quantity or colour of sputum, then it indicates bacterial infection. In these conditions, patients require antibiotics. Amoxicillin and Doxycycline can be used as first line drugs.

Amoxicillin/clavulanate, macrolides like azithromycin and clarithromycin, second generation cephalosporins can be used as an alternative second line agents. Fluroquinolones are better avoided. A course of Prednisolone 30-60 mg per day for 7-14 days is useful to shorten the duration of symptoms.

Indication for Hospitalisation:

Symptoms

Severe dyspnoea affecting day to day activities

Altered sensorium

New onset cyanosis

Signs

Use of accessory respiratory muscles

Paradoxical chest wall movements

Central cyanosis

Systolic BP < 90 mm Hg

Respiratory Rate 30/min

Heart rate> 110/min

Asterixis

Altered mental status

Spo2<90%

Others

Presence of severe comorbid conditions

Lack of social support.

Management in a hospital:

Intensification of inhaled bronchodilator treatment is done. Systemic corticosteroids and antibiotics are given. Oxygen therapy is given to maintain PaO2 > 60mmHg or SpO2 > 90%. Target oxygen saturation is 88-92%. If SpO2 is increased

beyond 92%, hypoxia induced ventilatory drive decreases and it may lead to hypoventilation resulting in further retention of CO2.

Till early 1960, only negative pressure ventilation was used for NIV in patients with neuromuscular disorder likes poliomyelitis and deformity of chest wall. In this, negative pressure was applied over chest through tank ventilator.

Later positive pressure ventilation was in use for patients with respiratory failure. Initially positive pressure was given through endotracheal tube alone.

Non-invasive ventilation

Administration of positive or negative pressure ventilation to lung through either mask or similar device without intubation. NIV can be administered safely in the ward itself; there is no need for intensive care unit. NIV decreases mortality in patients with acute exacerbation of COPD with arterial pH of < 7.35,

PaCO2 > 45mmHg (Type II respiratory failure) after medical management. It is indicated in these patients not responding to optimal medical management.

Indications:

Respiratory acidosis (arterial pH< 7.35 and or pCO2 >45 mm Hg)

Severe dyspnoea

Respiratory rate > 30/min

Use of accessory muscles of respiration

Presence of paradoxical breathing

Early NIV use has reduced the rates of intubation. It has also reduced length of hospital stay. It has also caused decline in mortality among COPD patients with exacerbations. During acute exacerbation of COPD, there is an imbalance is between respiratory load and capacity of the lung, producing exaggerated inflammation in the airways leading to spasm of bronchus, oedema of airways and more sputum formation. All these changes will increase the airway resistance, and lead to increase in work of breathing. Patients tend to respond with rapid, shallow, largely ineffective breath, leading to increased dead space ventilation.

Mechanical Ventilation:

If the patient does not respond to non-invasive ventilation, then invasive ventilation is chosen to treat the respiratory failure.

Indications for Mechanical Ventilation:

pH < 7.25

Failure of NIV

Respiratory or cardiac arrest

Hemodynamic instability

Life threatening hypoxia

Heart rate< 50/min

Complications due to invasive ventilation

1. The process of intubation and mechanical ventilation like injury to teeth, upper aerodigestive tract, arrhythmia, and hypotension.

2. Loss of airway defense mechanisms and impairment of airway ciliary function facilitate an easy passage to the microorganisms and other foreign materials to lower airways allowing their colonization leading to airway inflammation and damage.

3. After removal of the endotracheal tube- hoarseness of voice, sore throat, cough, sputum production, hemoptysis, upper airway obstruction and tracheal stenosis may occur.

AIMS

&

OBJECTIVES

AIMS:

1. To predict the relationship of blood eosinophils & serum IgE levels in COPD patients

2. To modify disease progression, hospital admissions & prediction of COPD exacerbations

OBJECTIVES:

1. To identify COPD exacerbations associated with elevated blood eosinophils

2. To correlate elevated blood eosinophils and serum IgE levels with exacerbation of COPD

MATERIALS

&

METHODOLOGY

METHODS & MATERIALS:

Source of data: COPD patients

Place of study: GHTM, Tambaram

Type of study: cross sectional observational study

Time of duration: 1 year (August 2016- August 2017)

After the informed written consent by the patients, study was proceeded with the approval of local ethical committee.

INCLUSION CRITERIA:

1. Symptoms –breathlessness, cough with expectoration, wheeze
2. Exposure to biomass and other inhalational injury
3. Occupational exposure to dust & fumes
4. Smokers and non-smokers

EXCLUSION CRITERIA:

1. Bronchial asthma patients
2. Asthma COPD overlap syndrome
3. Allergic to substances

4. Allergic conditions which predispose to elevated blood eosinophils and serum IgE levels

5. Exposure to pets

6. Treated tuberculosis

7. Known comorbidities - heart diseases, hypertension, malignancies

8. Family h/o bronchial asthma/atopic dermatitis

9. Individuals using or used oral corticosteroids or ICS-containing products

10. Regular drug intake other than bronchodilators & vitamin supplements.

Patients were screened with the help of inclusion & exclusion criteria. Eligible patients with a clinical diagnosis of COPD underwent spirometry.

The baseline spirometry was performed in subjects with sitting position and highest value of forced expiratory volume in 1 sec (FEV_1) and forced vital capacity (FVC) were obtained. Three acceptable values and at least two reproducible curves were obtained in each subject. Then salbutamol nebulization was given. Spirometry was repeated 20 min after administration of salbutamol. Reversibility was calculated in COPD patient groups. Patients showing FEV1/FEV <0.7 with NO significant reversibility was taken.

These patients underwent routine investigations – Complete blood count, liver function test, renal function test, sputum for AFB & culture sensitivity, Chest x-ray. Other investigations like CT chest, stool for ova cyst, peripheral smear was done to

rule out diseases like active Tuberculosis, Parasitic infestations, Eosinophilic pneumonias, Malignancy, Chronic eosinophilic leukemia.

Clinical findings, spirometry, radiology helped in ruling out ACOS (Asthma COPD overlap syndrome).

Absolute eosinophil count & serum IgE were done. Results were analyzed among 140 patients.

Based on GOLD criteria, COPD study population were classified into GOLD STAGE I,II,III,IV. Further based on ANTHONISEN's criteria, classification of STABLE COPD & COPD EXACERBATION was done.

Acute Exacerbation were defined according to the criteria of ANTHONISEN criteria:

Cardinal symptoms: dyspnea, sputum purulence, increased sputum volume.

OR

Atleast one cardinal symptom + anyone of the following:

1. Tachypnea
2. Tachycardia,
3. Wheeze
4. Upper respiratory tract infection,
5. Fever.

Exacerbations in the past one year was taken into consideration. Frequent exacerbation defined as exacerbations of 2 or more in the past one year. Infrequent exacerbation defined as exacerbations of less than 2 in the past one year.

STATISTICAL ANALYSIS:

Data analysis was done using SPSS software version 19.

A value of $P < 0.05$ was considered significant.

Comparison between two variables was done with chi square test.

OBSERVATION

&

RESULTS

CHART 1: GENDER DISTRIBUTION:



Chart 1: n = 140, Predominantly seen in males

CHART 2: AGE DISTRIBUTION:



Chart 2: n=140, Maximum in age group of 50 -70 yrs.

TABLE 1: PREVALENCE OF STAGE COPD & COPD EXACERBATION IN STAGE I,II,III,IV:

STAGE	COPD STABLE 53 (37.8%)	COPD EXACERBATION 87(62%)	P-VALUE
STAGE I (15%)	13	8	0.05
STAGE II (28.5%)	16	24	
STAGE III (41.4%)	19	39	
STAGE IV (15%)	5	16	

Table 1: n=140, predominantly seen in STAGE II & STAGE III

CHART 3 : PREVALENCE OF STAGE COPD & COPD EXACERBATION IN STAGE I,II,III,IV:



Table 1: n=140, predominantly seen in STAGE II & STAGE III

TABLE 2: COMPARISION OF VARIABLES BETWEEN STAGE I,II,III,IV:

Variables	Stage I (n=21)	Stage II (n=40)	Stage III (n=58)	Stage IV (n=21)
Age (mean)	63.3	61.75	60.7	61.1
Sex: • male	16	38	53	12
• female	5	2	5	9
Current Smoker	4	9	9	5
• Beedi	10	23	27	5
• Cigarette	6	8	14	4
Never smoker	3	8	12	4
Former smoker	12	22	32	5
Passive smoker	2	1	5	7
Pack years (mean)	12	16.16	15.1	20.3

Bronchodilators: • Yes	18	39	52	20
• No	3	2	6	1
Wheeze: • Yes	20	34	49	16
• No	1	6	9	5
Biomass exposure: • Current	8	16	31	8
• Former	13	23	26	13
• No	0	1	1	0
Duration of illness (mean) years	2.5	2.7	3.2	7.5
• <5 years	18	31	47	14
• 6 to 10 years	2	4	5	5

• >10 years	1	5	2	1
• No	0	0	4	1
Exacerbation in 1 year (mean):	N=8 0.61	N=24 1.3	N=39 1.4	N=16 1.76
• <2	7	17	26	9
• >2	1	7	13	7
• No exacerbation	13	16	19	5
Hospitalisation (mean):	2.6	4.1	2.9	3.1
No prior hospitalisation	10	11	17	8
FEV1 (%) (mean)	81.9	59	43.2	27
Chest X-ray				

• Emphysema	19	33	47	16
• Chronic bronchitis	2	7	11	5
Absolute eosinophil count (mean):	305.23	612.3	846.3	1065.3
Serum IgE	789.9	1728.4	1988.3	3246.8
Sputum culture sensitivity:				
• Influenza	3	8	8	4
• Moraxella	1	3	6	5
• Klebsiella	5	11	16	6
• Pseudomonas	3	5	4	4
• Others	0	4	4	0
• Normal	9	9	20	2

Ventilation:				
• Good	17	28	51	14
• Poor	4	12	7	7

Table 2: n=140, No. of exacerbations, Duration of illness, Eosinophil counts & serum IgE levels increased with stage I,II,III,IV respectively.

TABLE 3: COMPARISION OF VARIABLES BETWEEN STABLE COPD & COPD EXACERBATION:

VARIABLES:	STABLE COPD (n=53)	EXACERBATION COPD (n=87)
Age (mean)	61.2	61.6
Sex		
• Male	46	73
• Female	7	14
Current smoker	6	21
• Beedi	22	43

• Cigarette	15	17
Never smoker	11	16
Former smoker	31	40
Passive smoker	5	10
Pack years(mean)	13	17
Bronchodilators : • Usage	45	84
• No usage	8	3
Wheeze: • Yes	45	74
• No	8	13
Biomass exposure: • Current	26	37
• Former exposure	26	49

• No	1	1
Duration of illness (mean) years:	2.3yrs	4.18
• <5 years	39	71
• 6 to 10 years	4	12
• >10 years	7	2
• No	3	2
H/o of hospitalisations (mean)	3.4	3.3
No h/o of hospitalisation	30	16
FEV 1(mean)	54.3	48.9
Chest X-ray		
• Emphysema	39	76
• Chronic bronchitis	14	11

Absolute Eosinophil count (mean)	468.9	890.8
Serum IgE (mean)	1289.5	2309
Sputum culture sensitivity:		
• Influenza	8	15
• Moraxella	7	8
• Klebsiella	7	31
• Pseudomonas	7	9
• Others	3	5
• Normal	21	19
Ventilation:		
Good	47	63
Poor	6	24

Table 3: n=140, Increased bronchodilator usage in COPD exacerbation, Occupational & biomass exposure more in COPD exacerbation with lower FEV1 in COPD exacerbation.

TABLE 4: COMPARISION OF ABSOLUTE EOSINOHPHIL COUNT AMONG STABLE COPD & COPD EXACERBATION:

CUT OFF AEC (mean)	STABLE COPD	COPD EXACERBATION	P- VALUE
<2% (<300)	151.7	201.4	<0.001
>2% (>300)	632.1	970.4	

Table 4: n=140, > 2% / >300 seen in both stable COPD & COPD exacerbation but comparatively higher in COPD exacerbation.

TABLE 5: COMPARISION OF SERUM IgE AMONG STABLE COPD & COPD EXACERBATION:

CUT OFF S.IgE (IU/ml) (mean)	STABLE COPD	COPD EXACERBATION	P- VALUE
<150	65.7	0	<0.001
>150	1728.8	2309	

Table 5: n=140, >150 IU/ml seen in both stable COPD & COPD exacerbation but comparatively higher in COPD exacerbation.

TABLE 6: COMPARISON OF AEC & S.IgE AMONG STABLE COPD & COPD EXACERBATION:

VARIABLES	STABLE COPD	COPD EXACERBATION	P- VALUE
AEC (mean)	468.9	890.8	<0.001
S.IgE (mean)	1289.5	2309	<0.001

Table 6: n=140, mean of absolute eosinophil count (AEC) & serum IgE levels higher in stable COPD & COPD exacerbation.

TABLE 7: COMPARISION OF VARIABLES AMONG SMOKERS & NON SMOKERS:

Exposure to smoke	Duration of illness	No of hospitalisation	No of exacerbation	FEV1	AEC	S .IgE
SMOKER	3.9	2.62	1.35	51.5	747	2214
NON SMOKER	2.5	5.5	1	48.6	661	646.9

Table 7: n=140, Duration of illness, No of hospitalisation, Absolute eosinophil count & Serum IgE levels were higher among smokers compared to non smokers.

TABLE 8: COMPARISION OF VARIABLES WITH PACK YEARS:

Pack years	Duration of illness	No of hospitalization	No of exacerbation	FEV 1	AEC	S IgE
<10	2.9	2.42	1.02	52	689.3	1997
>10	4.24	2.63	2	54.69	771.6	2605

TABLE 8: Duration of illness, No of Exacerbations, Absolute eosinophil count & Serum IgE levels higher in >10 pack years.

TABLE 9: RADIOLOGICAL PREVALENCE AMON THE STUDY POPULATION:

CT CHEST	**NO.**
Localized bullae	21(15%)
Bronchial wall thickening	13(9%)
Centriacinar	57(41%)
Paraseptal	27(19%)
Panacinar	16(11.4%)
Irregular	6(4.28%)

Table 9: Most common radiological finding observed was Centriacinar & Paraseptal pattern. Irregular pattern seen the least.

DISCUSSION

In our study, we observed the significance of Blood Eosinophils & Serum IgE levels among the stable COPD & COPD exacerbation. We also observed the relation of these two biomarkers in the COPD exacerbation.

Study showed the male predominance 119(85%) & of female 21(15%) with the most common age group in the range of 50-70 years (83.5%) {CHART 1}

Prevalence of STAGE I 21(15%) in stable COPD 13(61.9%) & COPD exacerbation 8(38%), STAGE II 40 (28.5%) in stable COPD 16(40%) & COPD exacerbation 24(60%), STAGE III 58(41.4%) in stable COPD 19(32.7%) & COPD exacerbation 39(67%), STAGE IV 21(15%) in stable COPD 5(24%) & COPD exacerbation 16(76%). That is, predominantly seen in STAGE II & STAGE III. {TABLE 1}

The no of exacerbations in the last one year & duration of illness increased with staging I,II,III,IV. Whereas, the FEV1 declines with the stage I, II, III, IV. There was no much significant change in the hospitalisation between the various stages. {TABLE 2}

The absolute eosinophil count in STAGE I (305),STAGE II (612),STAGE III (846),STAGE IV (1065) & serum IgE levels in stage I (790),stage II (1728),stage III(1988),stage IV (3247). Here, the absolute eosinophil count & serum IgE levels increased with the staging respectively. {TABLE 2}

The factors like, occupational exposure to dust & fumes, biomass exposure & the poor ventilation were comparatively higher in COPD exacerbation states. {TABLE 3}

Whereas, bronchodilator usage was twofold higher in COPD exacerbation with mean of FEV1 in stable COPD (54.3) & COPD exacerbation (48.9) respectively. {TABLE 3}

The cut off of 2 % (300) for absolute eosinophil count and 150UI/ML for serum IgE levels was taken. Both the biomarkers were elevated in stable COPD & COPD exacerbation but comparatively higher in COPD exacerbation with the P value of 0.001 being statistically significant. {TABLE 4 & 5}

Like, previous studies showed the relationship between smoking & the elevation in the blood eosinophils & serum IgE levels. The cause for the elevation of the absolute eosinophil count & serum IgE levels was observed in our COPD study population. We could see that smoking was related with the elevation in the biomarkers. Especially, smokers (current, former, passive smokers) & patients with > 10 pack years were associated with increased duration of illness & increased exacerbation rates. {TABLE 6 & 7}

LIMITATIONS:

1. We did not analyse the difference in long-term drug therapy, particularly inhaled corticosteroids in these patients

2. We were not able to reproduce a correlation between sputum and blood eosinophils in a general population setting. Therefore, we cannot exclude that the correlation between sputum and blood eosinophils is different among relatively healthy, treatment-naive individuals with COPD from the general population

CONCLUSION

CONCLUSION:

1. Elevated blood eosinophils & serum IgE levels were observed in stable COPD & COPD exacerbation but comparatively was higher in COPD exacerbation. Hence, blood eosinophils can be used as a prognostic biomarker in COPD exacerbation.

2. Biomarkers allow the identification of patients who are most likely to respond to ICS

3. Smoking is related with longer duration of illness, increased exacerbations, elevated blood eosinophils & serum IgE levels.

4. Recurrent exacerbation of COPD is believed to accelerate disease progression and impairment of pulmonary function

5. Further, studies to be done to analyse biomarkers in COPD & ACOS.

6. Larger study population would provide better outcome

BIBLIOGRAPHY

BIBLIOGRAPHY:

1. Fishman's Pulmonary Disorders & Diseases, Fifth edition, volume 1

2. Definition and classification of chronic bronchitis for clinical and epidemiological purposes.

A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis.

Lancet 1965; 1: 775-9

3. American Thoracic Society. Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema.

Am Rev Respir Dis 1962; 85: 762-7

4. Snider GL, Kleinerman J, Thurlbeck WM, Bengali ZH.

The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of lung Diseases, workshop.

Am Rev Respir Dis 1985; 132: 182-5.

5. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al.

Small-airway obstruction and emphysema in chronic obstructive pulmonary disease.

N Engl J Med 2011; 365: 1567-75.

6. Halbert R J, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM.

Global burden of COPD: systematic review and meta-analysis.

Eur Respir J 2006; 28: 523-32.

7. Mahesh PA, Jayaraj BS, Prahlad ST, Chaya SK, Prabhakar AK, Agarwal AN, et al.

Validation of a structured questionnaire for COPD and prevalence of COPD in rural area of Mysore: A pilot study.

Lung India. 2009;26:63

8.GOLD guidelines 2017

9. Fore y BA, Thornton AJ, Lee PN.

Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

BMC Pulm Med 2011; 11: 36.

10. Lindberg A, Eriksson B, Larsson LG, Rönmark E, Sandström T, Lundbäck B, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample.

Chest 2006; 129: 879-85.

11. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J.

Developing COPD: a 25 year follow up study of the general population.

Thorax 2006; 61: 935-9.

12. Jindal S. K, Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, et al. Asthma Epidemiology Study Group. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and

environmental tobacco smoke exposure.

Indian J Chest Dis Allied Sci 2006; 48: 23-9.

13. Bjartveit K, Tverdal A.

Health consequences of smoking 1-4 cigarettes per day.

Tobacco Control. 2005;14:315–20.

14. Nicholas R .Anthonisen

"Lessons from the Lung Health study",Proceedings of the American Thoracic Society, Vol. 1,

Exacerbations in COPD and asthma: mechanisms and medicine (2004),pp. 143-145.

15. Hnizdo E, Sullivan PA, Bang KM, Wagner G.

Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: A study of data from the Third National Health and Nutrition Examination Survey.

Am J Epidemiology. 2002; 156:738–46.

16. Chhabra SK, Chhabra P, Rajpal S, Gupta RK.

Ambient air pollution and chronic respiratory morbidity in Delhi.

Arch Environ Health.2001; 56:58

17. Kan H, Heiss G, Rose KM, 37. Whitsel E, Lurmann F, London SJ, et al.

Traffic exposure and lung function in adults: the Atherosclerosis Risk in Communities study. Thorax 2007; 62: 873-9.

18. Decramer M, Janssens W, Miravitlles M.

Chronic obstructive Pulmonary disease.

Lancet 2012; 379: 1341-51

19. Vedel-Krogh S[1,2,3], Nielsen SF[1,2,3], Lange P[2,4,5], Vestbo J[6], Nordestgaard BG[1,2,3].

Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.
Am J Respir Crit Care Med. 2016 May 1;193(9):965-74. doi: 10.1164/rccm.201509-1869OC.

20. Tobias N. Bonten, Marise J. Kasteleyn, Renee de Mutsert, Pieter S. Hiemstra, Frits et al.

Defining asthma–COPD overlap syndrome: a population-based study
European Respiratory Journal 2017

21. Roberto de Marco, Alessandro Marcon, Andrea Rossi, Joseph

Asthma, COPD and overlap syndrome: a longitudinal study in young European adults
European Respiratory Journal 2015

22. Netsanet ANegewo1,Vanessa M McDonald1–4 et al

Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD

International journal of copd,1st july 2016

23. Dave Singh, Umme Kolsum, Chris E et al.

Eosinophilic inflammation in COPD: prevalence and clinical characteristics

European Respiratory Journal 2014

24. Vedel-Krogh S[1,2,3], Nielsen SF[1,2,3], Lange P[2,4,5], Vestbo J[6], Nordestgaard BG[1,2,3].

Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.

Am J Respir Crit Care Med. 2016 May 1;193(9):965-74. doi: 10.1164/rccm.201509-1869OC.

25. Umme Kolsum,[1] Gavin C. Donaldson,[2] Richa Singh,[2] Bethan L. Barker

Blood and sputum eosinophils in COPD; relationship with bacterial load

ReRespir Res. 2017; 18: 88.Published online 2017 May 8. doi: 10.1186/s12931-017-0570-5

26. Virender P. Singh Rathod, Prem Kapoor, K. K. Pillai, and Razia Khanam

Assessment of asthma and chronic obstructive pulmonary disorder in relation to reversibility, IgE, eosinophil, and neutrophil count in a University Teaching Hospital in South Delhi, India

J Pharm Bioallied Sci. 2010 Oct-Dec

27. Singh B[1], Arora S, Khanna V.

Association of severity of COPD with IgE and interleukin-1 beta.

Monaldi Arch Chest Dis. 2010 Jun;73(2):86-7.

28. Hogg JC, Macklem PT, Thurlbeck WM N

Site and nature of airway obstruction in chronic obstructive lung disease

Engl J Med. 1968 Jun 20;278(25):1355-60.

29. Tokuda Y, Miyagi S.

Physical diagnosis of chronic obstructive pulmonary disease.

Intern Med. 2007;46:1885–91.

30. Goddard PR, Nicholson EM, Laszlo G, Watt I (1982)

Computed tomography in pulmonary emphysema.

Clin Radiol 33:379-87

31.Cavigli E, Camiciottoli G, Diciotti S, et al.

Whole-lung densitometry versus visual assessment of emphysema.

Eur Radiol. 2009; 197:1686-1692

32. R. Siva, R. H. Green, C. E. Brightling

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial

European Respiratory Journal 2007

33. Bel EH[1], Ten Brinke A[2].

New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!

Chest. 2017 Jun 2. pii: S0012-3692(17)31022-X. doi: 10.1016/j.chest.2017.05.019.

34.. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al.

ATS/ERS Pulmonary Rehabilitation Writing Committee. American

Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation.

Am J Respir Crit Care Med. 2006;173:1390–413

35.Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation: A consensus conference report. Chest.

ANNEXURES

ETHICAL COMMITTEE PERMISSION LETTER

INSTITUTIONAL ETHICAL COMMITTEE, STANLEY MEDICAL COLLEGE, CHENNAI-1

Title of the Work	:	Elevated blood eosinophils and serum IgE levels as biomarkers in prediction of COPD exacerbations.
Principal Investigator	:	Dr. Lakshmi S Subedar
Designation	:	PG MD (TB & Respiratory Diseases)
Department	:	Department of TB & Respiratory Diseases Government Stanley Medical College, Chennai-01

The request for an approval from the Institutional Ethical Committee (IEC) was considered on the IEC meeting held on 26.09.2016 at the Council Hall, Stanley Medical College, Chennai-1 at 2PM

The members of the Committee, the secretary and the Chairman are pleased to approve the proposed work mentioned above, submitted by the principal investigator.

The Principal investigator and their team are directed to adhere to the guidelines given below:

1. You should inform the IEC in case of changes in study procedure, site investigator investigation or guide or any other changes.
2. You should not deviate from the area of the work for which you applied for ethical clearance.
3. You should inform the IEC immediately, in case of any adverse events or serious adverse reaction.
4. You should abide to the rules and regulation of the institution(s).
5. You should complete the work within the specified period and if any extension of time is required, you should apply for permission again and do the work.
6. You should submit the summary of the work to the ethical committee on completion of the work.

MEMBER SECRETARY, 14/10/16
IEC, SMC, CHENNAI
MEMBER SECRETARY
ETHICAL COMMITTEE,
STANLEY MEDICAL COLLEGE
CHENNAI-600 001.

PROFORMA

PERSONAL DETAILS:

Name of the patient :

Age/sex:

Address:

Occupation:

Ph.no.

HISTORY:

c/o breathlessness

c/o cough

c/o expectoration- colour, odour, quantity, consistency, blood stained/not

h/o haemoptysis

h/o wheeze

h/o atopy

h/o seasonal variation

h/o diurinal variation

h/o exposure to biomass

h/o weight loss/appetite

h/o bilateral pedal oedema/oliguria

h/o hospital admissions in the past one year

h/o frequency of exacerbations in the past one year

h/o of prior ATT

h/o any regular drug intake

h/o of usage of oral/inhaler corticosteroids

h/o asthma in family

VENTILATION:

Well aerated / poorly aerated

PERSONAL HABITS:

Smoker - yes/no. If yes, no. of cigarettes /bidis smoked per day

Alcoholic – yes/no

COMORBIDITIES:

Diabetes/Hypertension/Bronchial Asthma/Epilepsy/Heart Diseases

EXAMINATION:

GENERAL EXAMINATION

RESPIRATORY SYSTEM EXAMINATION:

DIAGNOSIS:

INVESTIGATIONS:

Routine blood investigation: CBC,LFT,RFT

Absolute eosinophil count

Serum IgE

Sputum for

1. AFB (Acid fast bacilli)

2. Culture & sensitivity

3. Cytology for malignant cells

Pulmonary function test

Chest X-ray

CT chest

Stool for ova/cyst

Peripheral smear

Signature of patient:

CONSENT FORM

I Mr / Mrs / Miss / _____ have understood the procedure read by the Doctors. I in my whole conscious awareness give consent for the procedure. I understand that the procedure is done in good faith for the best therapeutic results possible. I fully understand the consequences of the procedure. I can resign from the study at any point of time.

Signature

Name :

Date and Time :

Signature of Researcher :

CONSENT FORM (VERNACULAR LANGUAGE)

தகவல் அலகு

COPD என்ற நாட்பட்ட நுரையீரல் அடைப்பு நோய் தீவிரமடைவதை முன் கணிப்பதில் உயிர் குறியீடுகளான இரத்த ஈசினோபில்கள் மற்றும் சீரம் IGE அதிகரித்த அளவுகளின் பங்கு

ஆராய்ச்சியாளர் : மரு. லட்சுமி சுபேதார்

வழிகாட்டுனர் : மரு. இரா. ஸ்ரீதர்

மரு. வினோத்குமார்

மரு. நான்சிகுளோரி

மரு. வெங்கடகிருஷ்ணராஜ்

மரு. மகேஸ்வரன்

நோயாளியின் தகவல் கையேடு

நீங்கள் இந்த ஆய்வில் ஒரு அங்கத்தினராக சேர்ந்து கொள்ள அழைக்கப்படுகிறீர்கள். நீங்கள் இந்த ஆய்விற்கு உட்படும் முன்னர், நான் உங்களுக்கு பின்வரும் தகவல்களை அளிக்க விரும்புகிறேன்.

1. நாட்பட்ட நுரையீரல் அடைப்பு நோய் உள்ள நோயாளிகள் இந்த ஆய்வில் சேர்த்துக் கொள்ளப்படுவார்கள்
2. நோயாளியின் முழுமையாக நோய் விவரங்கள் நிர்ணயிக்கப்பட்ட படிவத்தில் சேகரிக்கப்படும்.
3. உடல் பரிசோதனையும், தேவையான மருத்துவ பரிசோதனைகளும் மேற்கொள்ளப்படும்.
4. இந்த முடிவுகள், ஆய்வு செய்யப்பட்டு, கல்வி நோக்கங்களுக்காக மட்டுமே பயன்படுத்தப்படும்.
5. ஒவ்வொரு நிலையிலும் உங்களுக்கு தேவையான தகவல்கள் அளிக்கப்படும். ஒவ்வொரு நிலையிலும் உங்கள் சந்தேகங்களுக்கு விளக்கமளிக்கப்படும்.
6. உங்களைப் பற்றிய விவரங்கள் இரகசியமாக பாதுகாக்கப்படும்.
7. எந்த தருணத்திலும் முன் அறிவிப்பின்ற தாங்கள் இந்த ஆய்வினை விட்டு விடைபெறலாம். இதனால் மருத்துவ ரீதியாகவோ சட்ட ரீதியாகவோ எந்த பாதிப்பும் தங்களுக்கு ஏற்படாது.

நான் தங்களை இந்த ஆய்வில் தன்னார்வ பங்கெடுத்து அழைக்கிறேன்.

நன்றி

ஆராய்ச்சியாளர் கையொப்பம் நோயாளியின் கையொப்பம்

மரு. லட்சுமி சுபேதார் பெயர்:

CONSENT FORM (VERNACULAR LANGUAGE)

ஒப்புதல் படிவம்

திரு/திருமதி/செல்வி :

வயது :

முகவரி :

தொலைபேசி/அலைபேசி :

சிகிச்சை விவரங்கள் :

திரு/திருமதி/செல்வி ஆகிய நான் கீழ்க்கண்ட விவரங்களை எனது தாய்மொழி வாயிலாக அறிந்து கொண்டேன்.

1. நாட்பட்ட நுரையீரல் நோய் தீவிரமடைவதை இந்த இரத்த பரிசோதனையின் மூலம் அறிந்து கொள்ளலாம் என்பது விளக்கப்பட்டது.
2. இந்த பரிசோதனை நோயின் தன்மை அறிந்து கொள்ள மட்டுமே பயன்படும் என்று விளக்கப்பட்டது.
3. இந்த பரிசோதனையின் பக்க விளைவுகள் விளக்கப்பட்டது.
4. இந்த பரிசோதனை மரு. லட்சுமி சுபதார் மூலம் மேற்கொள்ளப்படும்.

என் முழுமனதோடும், சுய நினைவோடும் இதன் முழு விவரங்களை அறிந்து கொண்டும் இந்த பரிசோதனைக்கு சம்மதிக்கிறேன்.

சிகிச்சை பெறுபவரின் கையொப்பம்/

இடது பெருவிரல் ரேகை

சாட்சிகள் :

பெயர் :

தேதி :

கையொப்பம்

PLAGIARISM SCORE:



Urkund Analysis Result

Analysed Document: thesis final copy.docx (D31191811)
Submitted: 10/10/2017 5:54:00 PM
Submitted By: lakshmisubedar@gmail.com
Significance: 2 %

Sources included in the report:

ROL final with correction copy.docx (D30568577)
GOLD COPD Pocket-Guide-20162.pdf (D21965804)
Web-version Thesis_Irma.pdf (D21846221)
Anshul thesis final.docx (D30681320)
220316 - Draft 4 - Trevor Hong - The susceptibility of COPD patients to viral respiratory infection.docx (D19053979)

Instances where selected sources appear:

11

MASTER CHART

NAME	AGE	SEX	OCCUPATION
kuppuswamy s/o lakshmanan	65	male/7941	gardener
madivelu s/o munuswamy	69	male/1117	leather factory
mani s/o ramaswamy	62	male/16273	farmer/security
arumugam/s/o chitri	57	male/1655	construction
gopal s/o vittal	62	male/17095	temple servant
natarajan s/o ramaswamy	59	male/32913	farmer
gopal s/o subrayan	60	male/25082	construction
srrenimuttu s/o karupaiah	65	male/1855	farmer/shopkeeper
karunakran s/o ranganathan	50	male/22270	barbar
raja s/o devraj	50	male/33148	cook/painter
murugesan/arumugam	46	male/1563	farmer
devaraj s/o sampath	64	male/28519	farmer
kaniyappans/o kuppareddy	60	male/3362	farmer
pacchai s/o chitrai	70	male/2066	farmer
bhupathy s/o srinivasan	60	male/2758	opticals shop
parndaman s/o jnanachandiran	41	male/15262	auto driver
devdas s/o velayudam	62	male/23	farmer
perumal s/o narayanan	67	male/164	farmer
subramanis/o munuswamy	70	male/1819	security
iyyavu s/o chinnaaih	65	male/1750	const/security
devaraju s/o krishnappanaidu	59	male/2689	farmer
kannan	55	male/16013	farmer
chinnapan	56	male	farmer
perumal	80	male	security
maasilamani s/o	65	male/17363	farmer
ponnuswamy s/o muttuswamy	55	male/17132	farmer
manikyam s/o ponnurangam	60	male/17136	brush painting
venugopalan s/o subrayan	72	male/21867	farmer
kasi s/o krishnakumar	60	male/100	loader
devraj s/o chamman	67	male/28519	farmer
veeraswamy s/o vellaiyan	72	male/613/17	iron store
palani s/o subramani	74	male/25066	cook
mohan s/o varadhan	66	male/23952	security
kanniyappan s/o arumugan	54	male/15041	construction worker
kaasolai	70	female	homemaker
ramachandran	61	male	farmer
murugan s/o arumugam	67	male/43929	farmer
durai s/o samikannu	62	male/ 43959	farmer
sharada	61	female	homemaker
chindamani s/o ganesan	64	male/43767	woodcutter
narayanan	65	male	security
chinappan	59	male	farmer
mohd iqbal	60	male	security
ramamurthy	45	male	construction worker
samikan	67	male	leather factory
munuswamy	75	male	painter
annamalai	75	male	works in shipyard

gnanathikkam	55	male	cook
mani	55	male	hotel worker
siva	65	male	farmer
ethiraj	74	male	security
loganathan	55	male	flower vendor
rajabhaktar	65	male	farmer
ganesan	47	male	loadi n unlodaing
govindaswamy	55	male	security
muthu	75	male	brush painter
pandiyan	60	male/24336	tea vendor
subramani s/o babu	60	male/47360	farmer
elumalai s/o rangaswamy	62	male/313	farmer
subramani s/o krishnan	56	male/47372	farmer
munuswamy s/o jaganathan	61	male/2665	loading
samikannu s/o dhanagopal	55	male/40513	farmer
sekar	60	male	farmer
arumugam	74	male	construction worker
parsuraman	70	male	loading
elangovan	48	male	fruit vendor
manickam	67	male	farmer
shanmugam	60	male	farmer
krishnapillai	60	male	farmer
balaraman	67	male	lorry driver
govindan	75	male	shop keeper
karpagam	55	female	flower vendor
sarvanan	79	male	polishing utensils
venugopal s/o krishnaswamy	61	male	fisherman
perumal s/o jayaram	67	male	construction worker
chandra s/o nagappan	67	female	housewife
vanaja	65	femlae	housewife
sampath s/o manikyam	60	male	security
kanamma d/o gopal	60	female	farmer
dhanasekaran s/o pavada	53	male	construction worker
vasantha d/o kandaswamy	65	female	housewife
palani s/o arumugam	70	male	goldsmith
meenachisundaram s/o subramani	64	male	ricemill worker
vimala d/o ratinam	58	female	housewife
saroja	57	female	farming
radha	58	female	housewife
munuswamy s/o manickam	64	male	cook
karupuswamy s/o chellaiah	57	male	security
venugopal s/o krishnaswamy	58	male	farmer
kannan s/o jayaraman	50	male	auto driver
nagaraj s/o rangaswamy	52	male	driver
kumar s/o ganesan	49	male	cook
madhan	58	male	cook
kumar s/o ganesan	65	male	farmer
chinnapan	60	male	auto driver

kanniyappan	58	male	farmer
murugesan/arumugam	67	male	security
manikyan	68	male	farmer
perumal	74	male	hotel woker
kannan	65	male	corporation worker
kuppuswamy	56	male	cook
manikantan	55	male	farmer
chhinnaswamy	56	male	security
sampath	50	male	constable
chandrasekar	65	male	cobbler
kanniyappan	66	male	farmer
yes	54	male	auto driver
	55	male	farmer
	67	female	auto driver
	68	male	security
	65	male	farmer
	58	male	farmer
	60	femlae	housewife
	65	male	loader
	70	femlae	farmer
	58	male	mill worker
	55	female	farmer
	57	male	hotel worker
	68	femlae	housewife
	57	male	cook
	58	female	cook
	58	male	cobbler
	69	male	welder
	67	female	housewife
	56	female	maid
	50	female	maid
	55	male	security
	59	male	farmer
	68	male	security
	66	male	mill worker
	59	male	painter
	57	male	farmer
	60	male	security
	63	male	construction worker
	62	male	construction worker
	58	male	lorry driver
	58	female	housewife
	59	female	housewife
	59	male	auto driver
	62	male	security

SMOKER	pack yrs	ALCOHOLIC	EXPOSURE TO BIOMASS	FAMILY H/O
former	8	yes	yes	no
no	no	no	yes	no
former	12	former	yes	no
former	10	former	yes	no
former	20	former	yes	no
former	10	former	yes	no
no	no	yes	yes	no
former	9	former	former	no
former	8	no	former	yes
former	12	former	YES	no
former	14	former	present	no
former	10	former	yes	no
former	10	former	yes	no
former	10	former	yes	no
former	10	former	former	no
no	no	no	former	no
former	14	former	yes	no
former	12	former	yes	no
former	10	former	former	no
former	15	former	former	no
no	no	no	former	no
former	2	former	former	no
former	14	former	former	no
former	60	former	former	no
no	no	former	yes	no
no	no	former	yes	no
former	13	former	yes	no
former	20	former	yes	no
no	no	former	former	no
former	8	former	former	no
former	10	former	former	no
former	~~19~~	former	former	no
former	8	former	former	no
former	50	former	former	no
passive	no	no	former	no
former	8	former	former	no
former	15	former	former	no
former	9	former	yes	no
no	no	no	former	no
former	6	former	yes	no
former	24	former	former	no
former	10	no	former	no
smoker	20	former	former	no
smoker	24	alco	former	no
former	15	ALCO	former	no
former	20	former	former	no
former	10	alco	former	no

former	12	former	former	no
smoker	20	former	yes	no
smoker	16	former	former	no
former	30	former	former	no
former	22	no	yes	no
former	16	no	former	no
smoker	10	no	former	no
smoker	22	former	former	no
former	20	former	former	no
former	15	former	former	no
no	no	no	former	no
smoker	7	former	former	no
smoker	30	former	former	no
former	16	former	former	no
no	no	no	former	no
former	20	former	yes	no
former	10	former	yes	no
former	16	former	yes	no
former	23	former	former	no
former	10	former	former	no
smoker	20	former	yes	no
smoker	20	former	former	no
former	20	former	former	no
smoker	8	former	former	no
passive	no	no	yes	no
former	30	former	yes	no
former	12	no	former	no
former	22	no	former	no
no	no	no	former	no
passive	no	no	former	no
former	10	former	yes	no
passive	no	no	yes	no
no	no	no	yes	no
no	no	no	yes	no
former	13	former	no	no
former	16	former	no	no
no	no	no	yes	no
passive	no	no	yes	no
passive	no	no	yes	no
former	9	former	yes	no
former	20	former	yes	no
no	no	former	yes	no
former	10	former	yes	no
former	15	no	yes	no
former	10	former	yes	no
former	12	former	former	no
former	7	former	yes	no
no	no	alco	former	no

former	8	alco	former	no
former	6	former	yes	no
former	10	former	former	no
smoker	20	former	former	no
no	no	former	yes	no
former	8	former	yes	no
former	10	former	former	no
no	no	former	yes	no
former	16	alco	yes	no
smoker	10	alco	yes	no
smoker	20	former	former	no
smoker	10	former	yes	no
smoker	10	former	former	no
passive	no	no	yes	no
smoker	20	former	yes	no
smoker	10	alco	former	no
non smoker	no	former	former	no
passive	no	no	yes	no
smooker	10	alco	yes	no
passive	no	no	yes	no
smoker	20	no	former	no
former	no	no	former	no
smoker	14	alco	yes	no
passive	no	no	former	no
non smoker	no	alco	former	no
passive	no	no	yes	no
former	15	former	former	no
smoker	16	alco	former	no
passive	no	no	yes	no
no	no	no	former	no
passive	no	no	former	no
smoker	16	former	former	no
smoker	10	former	former	no
smoker	15	former	yes	no
former	16	former	yes	no
former	25	former	yes	no
no	no	former	former	no
smoker	30	former	former	no
smoker	40	alco	former	no
non smoker	no	former	yes	no
non smoker	no	alco	former	no
passive	no	no	yes	no
passive	no	no	former	no
non smoker	no	alco	former	no
non smoker	no	alco	yes	no

H/O ATOPY	H/O WHEEZE	HOSP ADMISSION	EXACERBATIONS	PRIOR ATT
no	no	1	1	no
no	yes	20	3	no
no	yes	3	1	no
no	yes	1	0	no
no	yes	3	0	no
no	yes	1	0	no
no	yes	20	0	no
no	yes	2	0	no
no	yes	6	0	no
no	yes	1	0	no
no	yes	no	0	no
no	yes	1	0	no
no	yes	1	0	no
no	yes	2	0	no
no	yes	no	0	no
no	no	no	0	no
no	yes	1	0	no
no	yes	1	0	no
no	no	no	0	no
no	yes	no	0	no
no	yes	1	0	no
no	yes	2	0	no
no	yes	1	0	no
no	yes	2	1	no
no	no	no	1	no
no	yes	15	0	no
no	no	0	1	no
no	yes	4	0	no
no	yes	4	0	no
no	yes	2	0	no
no	yes	2	1	no
no	yes	1	0	no
no	yes	4	1	no
no	yes	10	4	no
no	yes	no	0	no
no	yes	3	1	no
no	yes	2	1	no
no	yes	1	1	no
no	yes	1	0	no
no	yes	4	0	no
no	yes	5	2	no
no	no	0	3	no
no	yes	3	3	no
no	yes	3	4	no
no	yes	no	0	no
no	yes	no	0	no
no	yes	no	0	no

no	yes	2	2	no
no	yes	3	4	no
no	yes	2	3	no
no	yes	1	2	no
no	yes	3	5	no
no	no	no	3	no
no	no	no	3	no
no	yes	no	2	no
no	no	no	2	no
no	yes	5	1	no
no	yes	no	0	no
no	yes	no	0	no
no	yes	4	1	no
no	yes	no	0	no
no	yes	4	1	no
no	yes	3	2	no
no	yes	3	1	no
no	yes	2	2	no
no	no	1	3	no
no	yes	no	0	no
no	yes	4	2	no
no	yes	3	3	no
no	yes	2	4	no
no	yes	2	4	no
no	yes	no	3	no
no	yes	no	4	no
no	no	1	4	no
no	yes	1	3	no
no	yes	no	2	no
no	yes	3	3	no
no	yes	2	2	no
no	no	nil	0	no
no	yes	nil	0	no
no	yes	nil	0	no
no	yes	nil	0	no
no	no	1	1	no
no	no	1	1	no
no	no	1	1	no
no	yes	1	1	no
no	yes	no	0	no
no	yes	no	0	no
no	yes	1	1	no
no	yes	no	4	no
no	yes	3	3	no
no	yes	1	1	no
no	yes	no	4	no
no	yes	no	0	no
no	yes	no	0	no

no	yes	4	3	no
no	yes	2	2	no
no	no	no	2	no
no	yes	3	2	no
no	yes	2	2	no
no	yes	4	2	no
no	yes	2	1	no
no	yes	3	2	no
no	yes	no	0	no
no	yes	no	0	no
no	yes	nil	1	no
no	yes	no	0	no
no	yes	3	2	no
no	yes	3	1	no
no	yes	3	3	no
no	yes	4	2	no
no	yes	4	1	no
no	no	no	0	no
no	yes	4	2	no
no	yes	3	2	no
no	no	no	0	no
no	yes	no	2	no
no	yes	3	1	no
no	yes	10	1	no
no	yes	3	2	no
no	yes	4	1	no
no	yes	2	2	no
no	yes	no	3	no
no	yes	1	1	no
no	yes	6	2	no
no	yes	3	1	no
no	no	no	0	no
no	yes	4	2	no
no	yes	4	2	no
no	yes	3	3	no
no	yes	4	2	no
no	yes	4	3	no
no	yes	5	1	no
no	no	0	0	no
no	yes	6	3	no
no	yes	4	2	no
no	yes	no	0	no
no	yes	no	0	no
no	yes	4	2	no
no	no	3	0	no

RADIO	AEC	S. IGE
emphysema	728	2944
ch.bronchitis	746	923
emphysema	352	891
emphysema	405	4778
emphysema	826	2651
emphysema	346	413
emphysema	367	603
emphysema	584	267
emphysema	128	75
emphysema	429	113
emphysema	439	5000
emphysema	185	50.8
emphysema	285	1688
emphysema	456	333
emphysema	587	4458
emphysema	266	324
emphysema	335	292
ch.bronchitis	169	297
ch.bronchitis	789	3245
emphysema	207	356
ch.bronchitis	619	678
emphysema	451	25
emphysema	543	266
emphysema	832	1456
emphysema	538	789
emphysema	212	545
emphysema	426	800
ch.bronchitis	240	501
ch.bronchitis	100	71
emphysema	500	93
emphysema	240	2598
emphysema	45	84
emphysema	300	980
emphysema	100	1766
emphysema	35	76
emphysema	489	558
emphysema	100	456
emphysema	150	344
emphysema	207	66
emphysema	130	376
emphysema	1500	5638
emphysema	356	421
emphysema	455	628
emphysema	678	1264
emphysema	45	225
emphysema	56	84
emphysema	597	87

emphysema	213	964
emphysema	384	842
emphysema	567	836
emphysema	1800	2690
emphysema	890	1952
emphysema	900	1463
emphysema	316	1709
emphysema	216	543
emphysema	260	1676
emphysema	404	1543
ch.bronchitis	675	546
ch.bronchitis	620	38.5
ch.bronchitis	987	1798
emphysema	516	202
emphysema	544	344
emphysema	630	1854
emphysema	498	1475
emphysema	1012	1715
emphysema	918	7293
emphysema	538	165
emphysema	678	1895
emphysema	712	3065
emphysema	506	6702
emphysema	1798	6461
emphysema	580	789
emphysema	2800	6944
emphysema	654	1200
emphysema	3410	4786
ch.bronchitis	860	346
emphysema	1233	878
emphysema	1360	3345
ch.bronchitis	879	675
emphysema	930	467
ch.bronchitis	630	809
emphysema	897	2778
emphysema	1288	3478
emphysema	1040	870
ch.bronchitis	791	809
ch.bronchitis	980	1233
emphysema	400	987
emphysema	990	2888
emphysema	1490	767
ch.bronchitis	1960	3877
emphysema	879	3677
emphysema	1280	2889
emphysema	1877	2455
ch.bronchitis	456	1212
emphysema	112	245

emphysema	1165	3779
ch.bronchitis	1265	4533
emphysema	1545	3456
emphysema	657	2344
emphysema	567	1300
emphysema	1657	3243
emphysema	989	2466
emphysema	1200	989
ch.bronchitis	122	355
emphysema	187	23
ch.bronchitis	898	2879
emphysema	545	34
ch.bronchitis	800	2998
emphysema	799	2345
emphysema	690	2780
emphysema	800	3900
emphysema	798	988
ch.bronchitis	700	2341
emphysema	700	1900
emphysema	1200	2341
emphysema	1356	7669
emphysema	900	3988
emphysema	1511	2788
emphysema	890	1235
emphysema	987	567
ch.bronchitis	786	1230
emphysema	869	8786
emphysema	700	897
emphysema	811	899
emphysema	234	577
emphysema	1399	799
emphysema	1299	7878
emphysema	987	7657
ch.bronchitis	689	656
emphysema	709	8789
emphysema	910	6562
emphysema	1001	356
emphysema	1200	2468
ch.bronchitis	980	8278
emphysema	788	887
emphysema	1022	899
emphysema	309	878
emphysema	567	878
emphysema	678	987
ch.bronchitis	565	877

CT CHEST	FEV1	STOOL OVA	SP NT C/S
centriacinar	37.8	2944	normal
bronchial wall thickening	40	neg	normal
localised bullae	60.4	neg	normal
centriacinar	82	neg	influenza
centriacinar	56.4	neg	moraxella
centriacinar	33.4	neg	normal
centriacinar	57.3	neg	klebsiella
centriacinar	58.5	neg	normal flora
panacinar	57.3	neg	normal
centriacinar	68.2	neg	klebsiella
centriacinar	38	neg	morexella
paraseptal	40	neg	citro + morex
paraseptal	35.5	neg	influenza
centriacinar	58.9	neg	influenza
centriacinar	47	neg	klebsiella
centriacinar	26	neg	NORM
irregular	36.7	neg	influenza
bronchial wall thickening	38.5	neg	NORMAL
bronchial wall thickening	33	neg	NORMAL
paraseptal	34	neg	influenza
bronchial wall thickening	34	neg	NORMAL
paraseptal	80.1	neg	PSEUDO
paraseptal	55	neg	pseudomonas
paraseptal	35	neg	NORMAL
irregular	33.6	neg	normal
centriacinar	59	neg	normal flora
centriacinar	60	neg	pseudomonas
centriacinar	65	neg	NORMAL
centriacinar	63	neg	enterobacter
centriacinar	35	neg	moraxella
localised bullae	34	neg	moraxella
bullae	82.3	neg	klebsiella
bullae	82.1	neg	NORMAL
centriacinar	58	neg	influenza
bullae	80.3	neg	pseudomonas
centriacinar	62.2	neg	normal
bullae	80.1	neg	klebsiella
bullae	80.4	neg	pseudo
bullae	83.2	neg	NORMAL
bullae	82.1	neg	NORMAL
panacinar	38	neg	influenza
centriacinar	84.2	neg	NORMAL
centriacinar	63.4	neg	normal
paraseptal	56.6	neg	influenza
bullae	81.2	neg	NORMAL
bullae	83.6	neg	normal flora
bullae	84.5	neg	normal florl

centriacinar	57.6	neg	klebgnella
paraseptal	36	neg	moraxella
paraseptal	56.7	neg	klebsiella
centriacinar	43	neg	normal florj
paraseptal	38.5	neg	citro
paraseptal	58.8	neg	normal flora
localised bullae	37.9	neg	normal
centriacinar	85.5	neg	klebsiella
paraseptal	54.6	neg	klebsiella
paraseptal	58.7	neg	influenza
bronchial wall thickening	25.4	neg	influenza
bullae	33.5	neg	pseudo
bronchial wall thickening	337	neg	pseudo
bullae	55	neg	acitinobacter
bullae	44	neg	enterobacter
panacinar	40	neg	klebseella
panacinar	46	neg	klebsiella
panacinar	46.3	neg	klebsiella
panacinar	27	neg	klebsiella
bullae	44.3	neg	normal flora
panacinar	33.6	neg	klebshella
panacinar	23.4	neg	klebsiella
panacinar	23.5	neg	klebsiella
panacinar	26.4	neg	klebsiella
centriacinar	28.5	neg	moraxella
localised bullae	29.6	neg	klebsiella
paraseptal	33.5	neg	normal florp
paraseptal	28.4	neg	moraxella
multiple bullae	57	neg	influenza
centriacinar	32.5	neg	influenza
paraseptal	38.6	neg	normal flora
centriacinar	27.4	neg	influenza
centriacinar	36.5	neg	pseudomonas
centriacinar	81	neg	normal flora
centriacinar	55	neg	normal flor
centriacinar	36	neg	klebmeella
paraseptal	26	neg	influenza
paraseptal	39	neg	normal
centriacinar	29	neg	normal
paraseptal	45.6	neg	normal
centriacinar	62	neg	pseudomonas
paraseptal	43.6	neg	klebsiella
bronchial wall thickening	36.6	neg	normal
centriacinar	40	neg	normal florj
irregular	33.6	neg	normla
irregular	38.5	neg	klebmaella
bronchial wall thickening	38.5	neg	normal flors
centriacinar	66.2	neg	moraxella

paraseptal	48	neg	klebsiella
bronchial wall thickening	54.3	neg	klebsiella
localised bullae	52.3	neg	klebmaella
centriacinar	56.3	neg	klebpeella
centriacinar	59.3	neg	klebkaella
paraseptal	45	neg	klebkuella
panacinar	35	neg	klebmaella
bullous changes	35.6	neg	klebchella
centriacinar	80	neg	normal florh
centriacinar	82	neg	klebchella
panacinar	36.5	neg	klebsiella
centriacinar	82	neg	moraxella
centriacinar	58.3	neg	pseudo
centriacinar	83	neg	klebsiella
centriacinar	53	neg	acitinobacter
centriacinar	81	neg	h influenza
panacinar	29.3	neg	moraxella
bronchial wall thickening	43.2	neg	normla
centriacinar	28.6	neg	pseudo
centriacinar	26.4	neg	klebsiella
centriacinar	40	neg	klebsiella
centriacinar	24.7	neg	moraxella
centriacinar	37	neg	klebsiella
centriacinar	28	neg	pseudo
paraseptal	36.2	neg	strepto
bronchial wall thickening	27	neg	moraxella
centriacinar	57.2	neg	influenza
irregular	56.4	neg	klebsiella
panacinar	56.5	neg	pseudo
centriacinar	80	neg	influenza
paraseptal	33.5	neg	influenza
paraseptal	53.2	neg	klebsiella
panacinar	26	neg	pseudo
bronchial wall thickening	50	neg	influenza
centriacinar	37.4	neg	influenza
irregular	64	neg	influenza
paraseptal	36.5	neg	klebsiella
centriacinar	33.8	neg	influenza
bronchial wall thickening	29	neg	pseudo
paraseptal	35.6	neg	moraxella
panacinar	65	neg	cirobacter
centriacinar	36.6	neg	moraxella
centriacinar	29	neg	influenza
centriacinar	45.5	neg	pseudo
centriacinar	66.6	neg	moraxella

H/O NEBULISATION/TRT	ACOS	Form of tobaco	VENTILATION	MMRC GRADE
NO	no	no	good	1
on trt/neb/inhalers	no	no	good	1
on trt/neb/inhalers	no	3 beedi/day	good	1
no	no	4 beedi/day	good	0
on trt/neb/inhalers	no	10 beedi/day	good	1
on trt/neb/inhalers	no	10 beedi/day	good	2
on trt/neb/inhalers	no	no	good	1
on trt/neb/inhalers	no	20 beedi/day	good	1
on trt/neb/inhalers	no	6cig/day	good	0
on trt/neb/inhalers	no	10 beedi/day	good	2
no	no	5 beedi/day	good	2
on trt/neb/inhalers	no	4 beedi/day	good	1
on trt/neb/inhalers	no	5 beedi/day	good	2
no trt	no	5 beedi/day	good	1
no trt	no	5 packs of cig/day	good	2
on oral	no	no	good	3
on oral	no	24 beedi/day	good	1
on oral	no	24 beedi/day	good	0
no trt	no	3 cig/day	good	1
on orals	no	20 cig/day	good	1
on orals	no	no	good	2
oral	no	10 beedi/day	good	0
oral	no	10 beedi/day	good	1
ORAL	no	21cig/day	good	1
no	no	no	good	1
oral	no	no	good	1
oral	no	5 beedi/day	good	0
on orals	no	24 beedi/day	bad	1
inhaler	no	no	bad	1
inhaler	no	2 cigarette	good	2
inhaler	no	10 beedi/day	good	1
inhaler	no	2 pack cigar/day	good	0
inhaler	no	2 pack cigar/day	good	0
inhaler	no	2 pack cigar/day	good	1
inhaler	no	no	good	0
inhaler	no	10 beedi/day	good	1
inhaler	no	24 beedi/day	good	0
inhaler	no	24 beedi/day	good	0
inhaler	no	no	good	0
inhaler	no	15 beedi/day	good	0
oral	no	10 beedi/day	bad	2
oral	no	20 cig/day	good	1
oral	no	20 beedi/day	bad	1
oral	no	22 beedi/day	bad	1
oral	no	10 cig	bad	0
oral	no	12 cig/day	good	0
NO	no	8 beedi /day	good	0

oral	no	5 beedi/day	good	1
oral	no	12 beedi	good	2
oral	no	20 beedi/day	bad	1
oral	no	24 beedi/day	good	1
oral	no	23 beedi/day	good	2
oral	no	11 cig	good	1
NO	no	4 beedi/day	good	3
oral	no	7 beedi	bad	0
oral	no	10 beedi/day	good	1
oral	no	24 beedi/day	BAD	0
no	no	no	good	2
oral	no	24 beedi/day	good	2
oral	no	24 beedi/day	good	1
oral	no	24 beedi/day	good	2
oral	no	no	good	1
oral	no	12 cig/day	good	1
oral	no	10 beedi/day	good	2
oral	no	10 beedi/day	bad	2
inhaler	no	20 beedi/day	good	3
oral	no	10 beedi/day	good	2
oral	no	20 beedi/day	good	2
inhaler	no	12 cig/day	good	1
inhaler	no	20 beedi/day	bad	2
inhaler	no	4 cig/day	bad	2
inhaler	no	no	bad	1
inhaler	no	50 beedi/day	good	2
oral	no	3 cig/day	good	1
inhaler	no	24 beedi/day	good	2
inhaler	no	no	good	1
inhaler	no	no	good	2
oral	no	4 beedi/day	good	1
oral	no	no	good	2
inhaler	no	no	good	2
inhaler	no	no	good	1
inhaler	no	10 cig/day	good	1
oral	no	24 beedi/day	good	1
oral	no	no	good	2
inhaler	no	no	good	1
oral	no	no	good	2
oral	no	20 cig/day	good	0
oral	no	20 cig/day	good	2
inhaler	no	no	good	1
no	no	6 cig/day	good	1
inhaler	no	20 cig/day	good	1
inhaler	no	24 beedi/day	good	2
inhaler	no	20 beedi/day	good	1
oral	no	10 cig/day	good	1
inhaler	no	no	good	0

inhaler	no	10 cig/day	good	1
inhaler	no	20 beedi/day	good	0
oral	no	24 beedi/day	bad	2
oral	no	24 beedi/day	bad	1
oral	no	no	good	1
oral	no	20 cig/day	bad	2
oral	no	10 beedi/day	good	1
oral	no	no	good	2
inhaler	no	8 beedi /day	good	0
inhaler	no	5cig/day	bad	0
inhaler	no	24 beedi/day	good	3
inhaler	no	15 beedi/day	good	1
inhaler	no	20 cig/day	good	3
inhaler	no	no	good	4
inhaler	no	10 beedi/day	bAd	2
oral	no	20 beedi /day	bad	3
oral	no	no	good	2
inhaler	no	no	good	3
oral	no	15 cig/day	good	2
oral	no	no	bad	3
inhaler	no	15 beedi/day	good	3
inhaler	no	no	bad	4
inhaler	no	15 cig/day	good	4
inhaler	no	no	bad	4
inhaler	no	no	good	2
oral	no	no	good	1
inhaler	no	20 beedi/day	good	1
oral	no	24 cig/day	bad	1
inhaler	no	no	good	0
oral	no	no	good	2
inhaler	no	no	good	2
inhaler	no	20c cig/day	bad	2
inhaler	no	10 beedi/day	bad	2
oral	no	10 beedi/day	good	2
oral	no	15 beedi/day	good	1
oral	no	20 beedi/day	good	2
oral	no	no	bad	2
oral	no	20 beedi/day	bad	2
oral	no	24 cig/day	good	2
oral	no	no	good	1
inhaler	no	no	bad	0
inhaler	no	no	bad	1
inhaler	no	no	good	2
oral	no	no	bad	1
inhaler	no	no	good	2

GOLD STAGE	duration of symptoms	phone no	comorbidities
3	1 year	8681013470	no
3	15 years	9677026107	no
2	7 years	9790827174	no
1	2m	7708332893	no
2	6 years	7358529232	no
3	2 yesars	9092923583	no
2	15 years		no
2	2 years	8675528799	no
2	20 years	7092221282	no
2	3 years	8056909382	no
3	2m	no	no
3	3 years		no
3	2 years		no
2	6 months	9551401018	no
3	2 yrs	9940389966	no
4	1 year	9786399897	no
3	3 years	9751485435	no
3	3 years	9710466748	no
3	6months	8124420086	no
3	10 years	9791822747	no
3	2 years	9566009588	no
1	3 years		no
2	3 years		no
3	3 years		no
3	1 month	9538908027	no
2	20 years	9751901894	no
2	10 years	9597276955	no
2	14 years	9500814323	no
2	2 years	9841239705	no
3	2 years	9566431614	no
3	10 years		no
1	5 years		no
1	6 years		no
2	10 years	9710217454	no
1	7 years		no
2	3 years		no
1	1 year		no
1	1 year		no
1	2 years		no
1	5 years		no
3	3		no
1	3		no
2	3		no
2	3		no
1	2		no
1	2		no
1	2		no

2	3		no
3	3		no
2	3		no
3	5		no
3	3		no
2	3		no
3	2		no
1	4		no
2	3		no
2	3	9940223230	no
4	3		no
3	2 years	9551993903	no
3	3 years	9629982025	no
2	2 years	7708606616	no
3	3 years	9940448377	no
3	6months		no
3	3		no
3	3		no
4	3		no
3	2		no
3	4		no
4	10		no
4	15		no
4	8		no
4	7	7200907710	no
4	7		no
3	5	9551605145	no
4	7		no
2	6 months		no
3	3 years		no
3	2 years	8015064338	no
4	3m		no
3	10 years		no
1	20 years		no
2	15 years		no
3	5		no
4	5 years		no
3	1year		no
4	1 year		no
3	15 years		no
2	5 years		no
3	3 months		no
3	3 months		no
3	6 years		no
3	2 years		no
3	4 months		no
3	3 minths		no
2	3		no

3	3	non
2	2	no
2	2 senths	no
2	2	no
2	2	no
3	2	no
3	no	no
3	2	no
1	2	no
1	2	no
3	no months	no
1	3	no
2	2 yrs	no
1	4 yrs	no
2	2 yrs	no
1	3 yrs	no
4	4 yrs	no
3	no	no
4	1 yr	no
4	2 yrs	no
3	no	no
4	3 yrs	no
3	2 yrs	no
4	3 yrs	no
3	2 yrs	no
4	3 yrs	no
2	2 yrs	no
2	4 yrs	no
2	3 yrs	no
1	2 yrs	no
3	4 yrs	no
2	1 YR	no
4	2 yrs	no
2	2 yrs	no
3	3 yrs	no
2	2 yrs	no
3	3 yrs	no
3	5 yrs	no
4	no	no
3	6 yrs	no
2	4 yrs	no
3	3 yrs	no
4	4 yrs	no
3	3 yrs	no
2	2 yrs	no